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In recent years, there is increasing interest in the use of herbal health products as 
an alternative to erectile dysfunction drugs to enhance sexual performance. 
Adverse events associated with the consumption of herbal products for sexual 
performance enhancement and treatment of erectile dysfunction have been 
reported. In Singapore, four illegal sexual performance enhancement health 
products have been reported to be adulterated with sildenafil and a very high dose 
of glibenclamide. These products have caused severe hypoglycaemia leading to 
10 deaths in Singapore.  
 
The objectives of this study are to assess the safety and quality of sexual 
performance enhancement herbal health products illegally sold in the red-light 
districts in Singapore and to develop analytical methods to enhance the adulterant 
testing capability in a national quality control laboratory. 
  
The first part of the study assessed the safety and quality of the sexual 
performance enhancement herbal products in Singapore. This part of the work 
involved adulterant screening of 247 illegal sexual enhancement health products 
seized by Health Sciences Authority (HSA) during the period Feb to Dec 2008 
from makeshift stalls in red-light districts of Singapore and a shipment at the 
Singapore Customs. The extent of adulteration, contamination and content level 




such products were also evaluated. The extensive list of adulterated products 
tested and the assessment results will be useful to consumers, regulators and the 
industry players. 
 
The second part of the project involved the development of a LC-Hybrid Tandem 
MS method for the detection of PDE-5 inhibitors and their related analogues in 
herbal health products marketed for sexual performance enhancement. The 
method developed was able to screen for the 3 approved PDE-5 inhibitor drugs 
(Sildenafil, Tadalafil and Vardenafil) and their related 22 analogues in sexual 
enhancement health products in 20 min. The developed screening method was 
validated using 11 blinded samples (consisting positive and negative products 
previously tested by HSA’s laboratory) and the validation results showed that the 
screening method was rapid, sensitive, specific and was able to simultaneously 
detect the PDE-5 inhibitors and related analogues present in the samples. To the 
best of our knowledge, this is thus far the only method that can provide such 
comprehensive screening of the PDE-5 inhibitors and their related analogues. 
 
The final part of the project involved the structural elucidation of an unknown 
adulterant detected in a herbal health product claimed for female sexual 
performance enhancement. The product was sent by a client to HSA for testing. 
The chemical structure of the unknown compound with molecular mass of 390 
was structurally elucidated using LC-DAD, LC-LTQ Orbitrap XL FTMS, NMR 




hormonal treatment drug developed for pre-menopausal woman with hypoactive 
sexual desire disorder (HSDD). The New Drug application for flibanserin was 
rejected by FDA Advisory Committee for Reproductive Health Drugs as the 
efficacy was deemed not sufficiently robust to justify the risks, concerns over the 
safety signals and potential drug interactions. The results of this study enabled the 
local regulator to stop the adulterated health product from entering Singapore’s 
market and raised the awareness of the possible adulteration of flibanserin in 
health products claimed for female sexual performance enhancement.  
 
The work presented in this thesis is useful to consumers, regulators, health care 
professionals and industry players. The method developed and validated has 
helped to enhance the testing capability of the national regulatory control 
laboratory in screening and detection of PDE-5 inhibitors, their analogues and 
other unknown adulterants found in health products claimed for sexual 
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1.1 Quality and safety of herbal medicines 
 
Herbal medicines are plant-derived materials or preparations with therapeutic or 
other health benefits, containing either raw or processed ingredients from one or 
more plants (Barnes 2003a, WHO 2005). Herbal supplements are a form of herbal 
medicines. 
 
Herbal medicines are widely used around the world. About 1.5 billion people 
worldwide use traditional Chinese herbal medicines (Hosbach et al. 2003). A 
survey conducted in 2005 (Jordan et al. 2010) revealed that 71% of Canadian used 
natural health products, which include herbal medicines, vitamins and minerals. 
11% of the people surveyed used herbal remedies and algal/fungal products. In 
the United States, about 19% of the adult population was using herbal medicines 
as of 2002 (Jordan et al. 2010, Kennedy 2005). Another study showed that about 
$17.8 billion was spent in the U.S. on dietary supplements with $4.2 billion of this 
amount on herbs (Dobos et al. 2005, NBJ 2002). 
 
Although herbal medicines are widely considered to be of lower risk compared to 
synthetic drugs, they are not completely free from the possibility of toxicity or 




such as Ephedra and Aristolochia is well known, adverse effects from the use of 
herbal medicines may also result from contamination of products with toxic 
metals, adulteration with pharmacologically active synthetic drugs, 
misidentification or substitution of herbal ingredients, or improperly processed  
products. Interactions may also occur between drugs, food and other herbal 
medicines taken concomitantly (Jordan et al. 2010).  The following sections 
discuss various quality and safety issues related to herbal medicines. 
 
1.1.1 Plant misidentification and substitution 
 
The correct identification of plant materials during collection and processing is 
critical for the quality control of herbal medicines. Substitution with more toxic 
herbs may occur due to misidentification of plant species or deliberately for 
economic reasons when a cheaper herb is supplied to replace a safe, more 
expensive one. Several cases of incorrect plant substitution or mis-identification 
have been reported. One example which resulted in significant morbidity, in 
particular, renal failure and renal cancer following the use of slimming products 
contaminated with Aristolochia species first surfaced in the 1990s, initially from 
Belgium, France and later UK (Barnes et al. 2002, EMEA 2002, Jordan et al. 
2010). This was due to the substitution of nontoxic herbs, including Stephania 





Koren et al. reported a case of maternal and neonatal androgenisation associated 
with a herbal product in 1990. The mother experienced increased hair growth on 
her head, forehead and public area. At birth, the male child had thick hair in the 
pubic region, and on the forehead, along with red swollen nipples. The mother 
had been taking a commercial product labeled as containing “Siberian ginseng” 
during her pregnancy and 2 weeks of breast feeding (Koren et al. 1990). Awang 
later investigated the case and found that the raw materials used did not contain 
authentic Siberian ginseng (Eleutherococcus senticosus (Rupr. And Maxim.) 
Maxim.), but were likely to contain silk vine (Periploca sepium Bunge, 
Apocynaceae) instead. It had previously been known that some Periploca species 
had been substituted for Eleutherococcus in some imported products, possibly due 
to confusion of the Chinese names of the two plants (Awang 1991, Jordan et al. 
2010). The Chinese name for Eleutherococcus senticosus is “Ci-wu-jia” (刺 五 
加), while the Chinese name for Periploca sepium is “wu-jia” (五 加), which may 
explain the source of confusion (Boon and Smith 2004). 
 
A similar case was reported in 2004. A 60-year-old man was diagnosed with 
kidney failure and cancer of the urinary tract in Hong Kong (Zhao et al. 2006, 
Liang et al. 2006). He had been taking a herbal prescription called “Bai Mao 
Teng” (白毛藤). Investigation by HKSAR Department of Health revealed that the 
patient had been mistakenly given Aristolochia mollissima Hance (Xun Gu Feng, 
寻 骨 风). Aristolochia mollissima Hance is known to contain aristolochic acid. 




erroneously substituted for Solanum lyratum Thunb (Bai Ying, 白 英) at the 
wholesale level as both the crude drugs have the same common names “Bai Mao 
Teng” (白毛藤). It was also found that there is recurring confusion with regard to 
the names Xun Gu Feng, Bai Ying and Bai Mao Teng. In light of this, the 
HKSAR Department of Health called for a suspension of the use of these 3 
Chinese herbs (Liang et al. 2006).  
 
1.1.2 Plant toxicity 
 
There is a common misconception that because herbs are natural, they are entirely 
‘safe’. Clearly, this is not the case (some plants are inherently poisonous), and 
plants used medicinally do, in some cases, cause adverse effects. Paracelsus, 
sometimes called the Father of Toxicology, had also in his famous quote, “Poison 
is in everything, and nothing is without poison; only the dose permits something 
not to be poisonous” said that substances considered toxic are harmless in small 
doses, and conversely an ordinarily harmless substance can be deadly if over-
consumed. This applies to the toxicity of herbal medicines. In general, little is 
known regarding the adverse effect of most herbal medicines. 
  
Digitalis species, Rauvolfia serpentine (L.) Benth. ex Kurz. (Apocynaceae), 
Atropa belladonna and Strychnos nux vomica L. (Strychnaceae), among others, 
are toxic plants but they are useful therapeutic agents when used appropriately 




plants that persistently evoke moderate to severe reactions, and should not be 
employed in any medical therapy. Plants including species of Sebecio, Crotalaria, 
and Symphytum, which contain pyrrolizidine alkaloids having an unsaturated 1,2-
double bond in the pyrrolizidine ring, should be avoided due to the hepatotoxic 
effect of these compounds (Denham 1996, Fong 2002).   
 
Aristolochia species are examples of plants containing toxic chemical constituents 
that should not be used medically. Aristolochic acid I, found in all species of 
Aristolochia investigated to-date, has been identified as a potent carcinogen and 
nephrotoxin (Fong 2002, Menges and Stotzem 1993, Menges and Stotzem 1992, 
Vanherweghem et al. 1993). Renal failure, nephritis, and urinary tract neoplasm 
have been associated with the use of Chinese and Kampo herbal medicines that 
contain Aristolocia species (Chen 2000, Fong 2002, Hashimoto et al. 1999, 
Nortier et al. 2000, Vanherweghem et al. 1993). 
 
In 2001, 30 cases of hepatotoxicity, ranging from abnormal liver function to liver 
failure, associated with the use of kava extracts were reported in Germany and 
Switzerland. One case was fatal and five others required liver transplants. 
Although it is difficult to assess causality in these cases as the evidence is 
complicated by other factors such as the use of concomitant drugs which may also 
cause liver toxicity. However, by July 2002, the Medicines Control Agency 
(MCA) in UK had received 68 case reports of hepatotoxicity worldwide, 




in UK revealed that the benefit-risk profile of kava appeared to be negative and on 
13 January 2003, a statutory order came into effect in UK prohibiting the sale, 
supply and import of unlicensed medicines containing kava (Barnes 2003b). 
Singapore has also banned the sale of kava products.     
 
1.1.3 Interactions with conventional drugs  
 
In recent years, it has become increasingly clear that even therapeutically safe 
herbs can manifest toxic effects as a result of herb-drug interaction, when 
administered concomitantly with synthetic pharmaceutical agents. Since 1999, 
evidence emerged of pharmacokinetic interactions between St John’s wort 
(Hypericum perforatum) products and certain drugs, including anticancer agent 
(imatinib and irinotecan), anti-HIV (e.g indinavir, lamivudine and nevirapine), 
anti-inflammatory agents (e.g ibuprofen and fexofenadine), antimicrobial agents 
(e.g erythromycin and voriconazole), cardiovascular drugs (e.g digoxin, 
ivabradine, warfarin, verapamil, nifedipine and talinolol), central nervous system 
agents (e.g amitriptyline, buspirone, phenytoin, methadone, midazolam, 
alprazolam, and sertraline), hypoglycaemic agents (e.g tolbutamide and 
gliclazide), immuno-modulating agents (e.g cyclosporine and tacrolimus), oral 
contraceptives, proton pump inhibitor (omeprazole), respiratory system agent 
(theophylline), statins (e.g atorvastatin and pravastatin) (Di et al. 2008, Zhou et al. 
2004, Barnes et al. 2001a). Both pharmacokinetic and pharmacodynamic 




2008). As St John’s wort is a potent inducer of cytochrome P450s (e.g CYP2C9 
and 3A4) and P-glycoprotein (P-gp), it is not surprise that many drugs that 
interact with St John’s wort are substrates of CYP3A4, CYP2C9 and P-gp. The 
combined use of St John’s wort with such drugs may enhance or reduce the 
bioavailability of the drugs. Interactions leading to synergistic therapeutic effects 
may lead to unfavorable toxicities and complicate the dosing regimen of long-
term medications. Antagonistic interactions will result in decreased efficacy and 
therapeutic failure (Di et al. 2008, Zhou et al. 2004).  
 
Panax ginseng has been reported to interact with phenelzine and other 
monoamine inhibitors causing central nervous system (CNS) stimulation (Chan 
2003, Jones and Runikis 1987). The anticoagulant effect of warfarin was 
decreased when Panax ginseng was also taken simultaneously (Chan 2003, 
Janetzky and Morreale 1997).  Digoxin levels were elevated in a patient who took 
a preparation labeled as Siberian ginseng, Eleutherococcus senticosus, but there 
was no sign of toxic effects (Chan 2003, McRae 1999). Danshen (Salvia 
miltiorrhiza) affected both the pharmacodynamics and pharmacokinetics of 
warfarin in rats (Chan 2003, Lo et al. 1992). Danshen prolonged the prothrombin 
time of warfarin, an indicator of anti-coagulation in the rat (Lo et al. 1992) ; 
increased the bioavailability and decreased the elimination of warfarin in the rat 
(Chan et al. 1995) ; inhibited CYP1A1, CYP2C6 and CYP2C11-mediated 
warfarin metabolism both in vitro and in vivo in the rats (Wu and Yeung 2010). 




pharmacokinetics of warfarin in rabbits (Chan 2003, Lo et al. 1995). There was no 
significant variation in the single dose pharmacokinetic parameters of warfarin 
were observed after Danggui treatment. However, prothrombin time of warfarin 
was significantly lowered after 3 days co-treatment with Danggui (Lo et al. 1995). 
 
Drug-herb interaction must be considered and monitored to promote a safe 
integration of efficacious herbal medicine into conventional medical practices. 
With a worldwide rise in the use of herbal preparations, more clinical data 
regarding herb-drug interactions are needed and herbs should be properly labeled 





The therapeutic components of plants vary depending on the part of the plant used, 
age, geographic area where the plant is grown processing methods, and storage 
conditions.  Therefore, batch-to-batch and manufacturer-to-manufacturer variation 
in preparations of the same herb will occur. With increased awareness in quality 
control of herbal medicines, some manufacturers now produce standardized 
herbal extracts as an approach to ensure batch-to-batch consistency. With 
standardization, products will contain a specific quantity of active constituent(s) 
and in some cases, unwanted or toxic constituents are removed.  For example, 




glycosides, 5-7% terpene lactones, and less than 5 parts per million of ginkgolic 
acids, which are known to be allergenic (Barnes 2003a). 
 
Although standardization is an important step for quality control, it is a challenge 
for many herbs whereby their active constituents are not known.  In these cases, 
products may be standardized based on the content of certain “marker” 
compounds (chemicals characteristic of the herb, or present in large quantities). 
However, this approach assumes that the unknown active constituents are 
standardized by standardizing the “marker” compounds (Barnes 2003a).  
 
Specifications for the quantities of the marker compounds for some herbal 
medicinal ingredients are set out in pharmacopoeias such as the United States 
Pharmacopoeia (USP 2010), the British Pharmacopoeia (BP 2010) and Chinese 
Pharmacopoeia (Committee of National Pharmacopeia of PR China 2010), which 
are recognized as the official compendia in their respective countries. WHO has 
also published guidelines on the quality of herbal medicines on Good 
Manufacturing Practices for herbal medicines (WHO 2007) and on Good 
Agricultural and Collection Practices (GACP) for medicinal plants (WHO 2003), 





1.1.5 Contamination  
 
Contamination of herbal medicines with high level of heavy metals, pesticides 
residues and micro-organisms are of safety concern. Heavy metal contamination 
can occur at the cultivation, post-harvest treatment, or product manufacturing 
stages. A review article (Koh and Woo 2000) reported excessive toxic heavy 
metals in Chinese proprietary medicines (CPM) in Singapore between 1990 and 
1997. Lead, arsenic and mercury have also been detected in CPM using ICP-MS 
and atomic absorption spectroscopy (Au et al. 2000). Heavy metals contamination 
in herbal medicinal plants and products were reported by Gasser and Street 
(Gasser et al. 2009, Street et al. 2008). Heavy metals may be intentionally added 
to products within specific traditional health paradigms such as Ayurveda (Ernst 
2002, Cooper et al. 2007, Jordan et al. 2010, Saper et al. 2008) and contamination 
may occur through inadequate quality control.   
 
Microbial contamination can occur during the collection and the processing of 
ingredients or finished products. Microbial species may be introduced due to poor 
quality control or hygiene practices (Jordan et al. 2010, Sagoo et al. 2009). 
Microbial contamination of herbal medicines including the health implications 
has been reviewed (Guédon et al. 2007a). The potential for microbial 
contamination of herbs may be increased by the use of manures in agriculture, 
including those which may contain toxic strains of Escherichia coli. The drying of 




microorganisms (WHO 2003). Fungal attack of plants can introduce mycotoxins 
in herbal medicines (Guédon et al. 2007b, Roy et al. 1988).   
 
A relatively limited number of reports exist about the presence of pathogenic 
microorganisms in herbal plants. Czech et al. has screened 138 medicinal herbal 
drugs for a broad spectrum of pathogens and indicator germs. It was shown that 
these microorganisms are relatively rarely found, with exceptions of Bacillus 
cereus and Clostridium perfringens. However, these two spore-formers usually do 
not present in magnitudes representing a real toxicity potential (Czech et al. 2001). 
Moulds like Penicillium, Aspergillus, Rhizopus, Mucor, Cladosporium and 
Aeruobasidium spp. were reported to be found quite often in herbal drugs (Kneifel 
et al. 2002). Considerable risk levels of aflatoxins were detected in several herbal 
medicinal samples of different taxa (Kneifel et al. 2002). Findings revealed that 
environmental conditions (climate, humidity, hygiene etc) largely contributed to 




One of the greatest safety concerns is the adulteration of herbal medicines with 
undeclared pharmaceutical drugs or their analogues, in illicit attempts to evade 
detection. It represents another problem in product quality and is one of the major 
causes for adverse events. In Taiwan, a large scale effort was initiated in 1992 to 




synthetic therapeutic substances (Huang et al. 1997). A total of 2,609 samples 
were collected from eight major general hospitals. Samples were collected 
through physicians’ referrals during patient visits. The study revealed that 23.7% 
of the samples collected were adulterated. More than half (52.8%) of the 
adulterated traditional Chinese medicines contained two or more adulterants.   
 
Herbal products for weight loss, erectile dysfunction and sexual performance 
enhancement are considered high risk products and are commonly found to be 
adulterated. Cases of weight loss products adulterated with sibutramine and 
fenfluramine were reported (Corns and Metcalfe 2002, Jung et al. 2006).  In 
Singapore, a 42-year-old female developed fulminant hepatic failure in 2002 after 
consuming a weight-reducing herbal product “Slim 10” containing fenfluramine, 
nitrosofenfluramine and thyroid gland extract over a period of approximately 4 
months (Lau et al. 2004).  In Japan, there were 12 cases of acute liver injury 
associated with the use of weight-reducing herbal products “Chaso” and 
“Onshido”, which were also found to be adulterated with nitrosofenfluramine. 
Two patients developed fulminant hepatic failure. One died and the other 
underwent a liver transplant (Adachi et al. 2001). The danger of consuming 
adulterated herbal products is obvious.      
 
The adulteration of health products for the treatment of sexual dysfunction and to 




5 inhibitors and their analogues will be further discussed in detail in Section 1.3 
of this Chapter. 
 
1.1.7 ADRs reporting 
 
There is a general misconception that “natural” always means “safe” and that 
remedies from natural origin are harmless. However, some medicinal plants are 
inherently toxic.  As with all medicines, herbal medicines are expected to have 
side effects, which may be of an adverse nature. Some adverse events reported in 
association with herbal products are attributable to problems of poor quality. 
Major cases of such events are adulteration of herbal products with undeclared 
other medicines and potent pharmaceutical substances. Adverse events may also 
arise from the misidentification of medicinal plants, incorrect dosing, errors in the 
use of herbal medicines both by health-care providers and consumers, interactions 
with other conventional drugs, and use of products contaminated with potentially 
hazardous substances, such as toxic metals, pathogenic microorganisms and 
agrochemical residues (WHO 2004).   
 
Pharmcovigilance for herbal medicines is in its infancy.  Generally, there is a lack 
of clinical trial data for herbal medicines and, in any case, controlled clinical trials 
have the power only to detect common, acute adverse effects. Adverse events thus 
far reported in relation to herbal products are frequently attributable either to poor 




distinguish genuine adverse reactions to herbal medicines and products until the 
cause of such events have been identified (WHO 2004). However, one of the 
recognized limitations includes the poor quality of some reports, and the difficulty 
in establishing causality (Barnes 2003b).   
 
Adverse events for herbal medicines are usually under reported, unlike those for 
conventional drugs. Due to the belief that herbal medicines are natural and safe, 
consumers may not associate ADRs with their use (De Smet et al. 1997). 
Furthermore, users of herbal medicines may be reluctant to report ADRs 
associated with these products to their doctors or pharmacists (Barnes et al. 1998), 
and some healthcare professionals may be unaware of the ADR reporting scheme 
(Barnes 2001b). Healthcare professionals may also hesitate to report ADRs as the 
causality is often difficult to establish.  
 
In recognizing safety monitoring as a critical component of quality control, WHO 
has upon the request by the members countries, developed the WHO guidelines 







1.2 Regulatory environment for herbal medicines   
 
A regulatory framework for herbal medicines provides consumers greater 
assurance that there has been an assessment of the safety, quality and efficacy of 
the products prior to granting of market authorization, and that the product is free 
from adulteration and within tolerance limits for contaminants. Requirements for 
Good Manufacturing Practices (GMP) provide a framework for assuring quality. 
Adverse reaction reporting facilitate the detection of any noxious and unintended 
responses from marketed health products.  
 
WHO conducted a global survey on the regulations of Traditional Medicine (TM), 
Complementary/Alternative Medicine (CAM) and Herbal Medicine (HM) (WHO 
2005). A total of 141 Member States participated in the survey. The survey 
revealed that a total of 92 Member States (65%) had laws or regulations for herbal 
medicines. The survey also indicated that most of the Member States (74%) 
treated herbal medicines as Over-the-counter medicines (O.T.C), which are 
allowed to be sold over-the-counter without doctor’s prescription. The finding 
revealed the difference in regulatory status in different countries. In addition, the 
safety assessment of the herbal medicines is usually based on the demonstrated 
safe traditional use or reference to documented scientific research on similar 





Four different regulatory frameworks, particularly from USA, Europe, China and 
Singapore are summarized below, to illustrate some common similarities and 
differences in the regulation of herbal medicines. 
  
1.2.1 Regulatory control of herbal medicines in USA 
 
Herbal medicines and supplements are regulated by US FDA under a category 
called “dietary supplements”. In recognition of vast consumer usage of dietary 
supplements, the US Congress passed the Dietary Supplement Health and 
Education Act (DSHEA) in 1994. The US Congress defined dietary supplements 
as products taken by mouth that contains "dietary ingredients" intended to 
supplement the diet (US FDA 2010a). The "dietary ingredients" in these products 
may include vitamins, minerals, herbs or other botanicals, amino acids, and 
substances such as enzymes, organ tissues, glandulars, and metabolites. Dietary 
supplements can also be extracts or concentrates, and may be found in many 
forms such as tablets, capsules, softgels, gelcaps, liquids, or powders. They can 
also be in other forms, such as a bar, but if they are, information on their label 
must not represent the product as a conventional food or a sole item of a meal or 
diet. Whatever their form may be, DSHEA places dietary supplements in a special 
category under the general umbrella of "food", not drugs, and requires that every 
supplement be labeled a “dietary supplement” (US FDA 2010a). The US FDA 




from those concerning the conventional prescription and OTC drugs (US FDA 
2010a).  
 
Under the DSHEA, the dietary supplement manufacturer is responsible for 
ensuring that a dietary supplement is safe (free from dangerous contaminants, 
adulterants or unsafe ingredients) and product label information is truthful and not 
misleading before it is marketed. There is no provision in the law for FDA to 
“approve” dietary supplements for safety or effectiveness before they reach the 
consumer. Hence, manufacturers do not need to register their products with FDA 
nor get FDA approval before producing or selling dietary supplements. Except in 
the case of a new dietary ingredient (a dietary ingredient which was not sold in 
the U.S. in a dietary supplement before October 15, 1994), where pre-market 
review for safety data and other information is required by law, the manufacturer 
has to notify and provide FDA with information, including any citation to 
published articles, which is the basis on which the manufacturer has concluded 
that a dietary supplement containing such dietary ingredient will reasonably be 
expected to be safe under the conditions of use recommended or suggested in the 
label of the product (US FDA 2010b). US FDA is responsible for taking action 
against any unsafe dietary supplement product after it reaches the market. FDA 
will have to show that a dietary supplement is “unsafe” before it can take action to 





Manufacturers will need to register themselves pursuant to the Bioterrorism Act 
with FDA before producing or selling supplements. In June, 2007, FDA published 
comprehensive regulations for Current Good Manufacturing Practices for those 
who manufacture, package or hold dietary supplement products (US FDA 2010d). 
These regulations focus on practices that ensure the identity, purity, quality, 
strength and composition of dietary supplements. 
 
FDA's post-marketing responsibilities include monitoring safety, e.g. voluntary 
dietary supplement adverse event reporting, and product information, such as 
labeling, claims, package inserts, and accompanying literature. The Federal Trade 
Commission regulates dietary supplement advertising. 
 
FDA regulations also require that certain information appear on dietary 
supplement labels. Information that must be on a dietary supplement label 
includes: a descriptive name of the product stating that it is a "supplement;" the 
name and place of business of the manufacturer, packer, or distributor; a complete 
list of ingredients; and the net contents of the product. In addition, each dietary 
supplement (except for some small volume products or those produced by eligible 
small businesses) must have nutrition labeling in the form of a "Supplement 






1.2.2 Regulatory control of herbal medicines in Europe 
 
In Europe, herbal medicines are considered a category of products used for 
therapeutic purposes that are derived from plants and plant materials. Herbal 
medicines are generally sold as food supplements and a common regulatory status 
in the various European countries does not exist. In March 2004, the European 
Directive 2004/24/EC on Traditional Herbal Medicinal Products (THMP) was 
released by the European Parliament and Council of Europe (Gioacchino 2008, 
Silano 2004). This directive is the basis of regulation for the future use of herbal 
medicines in Europe. The full application of the Directive in Europe is scheduled 
7 years after its release, and is currently in force.    
 
The Directive establishes that herbal medicines released in the market need  
authorization by the national regulatory authorities of each European country and 
these products must have a recognized level of safety and efficacy. (Gioacchino 
2008). The safety of herbal medicinal products will be evaluated on the basis of 
existing scientific literature (data from clinical studies, case reports, pre-clinical 
studies). The Directive also classified herbal medicines into two categories : (i) 
well established herbal medicinal products ; and (ii) traditional use herbal 
medicinal products. It requires the traditional use medicinal products to 
demonstrate at least 30 years of safe traditional use, including 15 years in the 
European Community (Dobos et al. 2005, Gioacchino 2008). Taking into 




Community, only a special simplified registration is required. This is based on 
specific standards of safety and quality, agreed indications based on traditional 
usage, and systematic patient information allowing the safe use of the product 
(Gioacchino 2008, Jordan et al. 2010).     
 
The Directive also requires that herbal products are produced according to GMP 
to ensure the quality of the product and also demonstrate safety and that these 
products should carry indications for use that are limited to minor medical 
conditions (Dobos et al. 2005). 
    
A new committee, the Herbal Medicinal Products Committee (HMPC), has been 
formed inside the European Medicines Agency (EMA) with responsibility for 
herbal medicinal products. HMPC members are generally but not exclusively 
nominated by the national regulatory agencies. HMPC prepares and releases 
documents useful to the implementation of the Directive such as list of herbal 
substances, preparations and combinations for use in traditional medicinal 
products and herbal monographs that provide scientific summary of all data 
available on the safety and efficacy of a herbal preparation intended for medicinal 
use. Information such as clinical indications, posology, method of administration, 
contraindications, precautions, interactions etc is included (Gioacchino 2008).     
 
The goal of harmonizing the legislative framework for market authorization of 




herbal medicines. However, the THMP Directive has led to a widespread industry 
opposition amongst herbal producers, practitioners and the public. The European 
Herbal Practitioners Association (EHPA) had submitted their response to the 
EMEA Consultation held on 30 September 2005, pointing out that the quality 
control guidelines proposed to be applied to traditional herbal medicinal products 
were unworkable for multi-herbal preparations and the costs of implementation of 
the Directive may see the demise of many small to medium sized herbal suppliers 
and manufacturers. In addition, the Directive discriminated against non-European 
Herbal Traditions by requiring at least 15 out of 30 years of usage within the 
European Community, as the basis for proving long established, traditional usage. 
This provision was deemed to seriously disadvantage Ayurveda, Tibetan and 
Traditional Chinese Medicines (EHPA 2005). Two non-government organizations, 
the Alliance for Natural Health International (ANH-Intl) and the European 
Benefyt Foundation (EBF) developed a joint position paper, stating a range of 
concerted actions which include improvement of the food supplement regime, 
judicial review of the European Directive 2004/24/EC on THMP and facilitation 
of a new regulatory framework for traditional medicinal products (Verkerk and 
Dhaenens 2010). An online petition was also called by ANH-Intl to challenge the 
THMP Directive (ANH-Intl 2011).  
 
A forum was organized by members of Greens/European Free Alliance on 21 Jun 
2011 in the European Parliament to seek clarification on THMP Directive and the 




argued in the forum that the drug registration system offered by the EU herbal 
directive provides no additional obstacles for products of non-European traditions, 
as compared with European ones. In addition, THMP Directive applies only to 
medicinal products, it does not regulate holistic traditions. Despite the efforts of 
clarification, participants were disappointed as they felt that their questions were 
not clearly addressed and explained in details.  ANH-Intl issued an open letter to 
EC three days after the forum to demand for immediate response and actions to 
revise the THMP Directive. It also plans to file a legal challenge at the High Court 
in London (ANH-Intl 2011). 
 
 
1.2.3 Regulatory control of herbal medicine in China 
 
Herbal medicines in China are classified into 2 groups: functional foods and drugs. 
Each differs in its applications, approval standards, production management, 
labeling, specifications, advertising, and overall supervision. There have been no 
comprehensive laws or regulations in China that standardize the manufacturing, 
processing, and marketing of functional foods such as health foods or 
supplements, except some aspects of these foods have been regulated in the 
Provisional Law of the People’s Republic of China on Food Hygiene (Liu and 





Crude traditional Chinese medicinal materials (plants, animal parts and minerals) 
and Chinese proprietary medicines (CPM) (the final dosage forms) are classified 
as drugs and the Drug Administration law requires these drugs to be evaluated for 
safety and efficacy. Drugs will have to be produced according to GMP standards, 
distributed and stored according to good distribution and storage practices (Liu 
and Salmon 2010). It is worthwhile to note that in China, synthetic drugs in CPM 
are allowed if the information is made known to the health authorities at the time 
of registration and is indicated in the package insert, subject to approval (Koh and 
Woo 2000). 
.  
The Pharmacopoeia of the People’s Republic of China defines the country’s drug 
standards. The 2010 edition contains 3 volumes. Volume I includes monographs 
for crude traditional Chinese medicinal materials, Chinese crude drug 
preparations (single ingredients) and Chinese proprietary medicines. Volume II 
deals with monographs of chemical drugs, antibiotics, biochemical preparations, 
radiopharmaceuticals and excipients for pharmaceutical use. Volume III contains 
monographs for biological products (Committee of National Pharmacopeia of PR 
China 2010). Volume I of the 2010 edition includes 2165 monographs, of which 
1019 are new entries compared with the previous 2005 edition. These 
monographs describe the sources, identification methods, and preparation 
processes for the traditional Chinese medicinal materials and proprietary 
medicines along with their utilization and major indications for use, dosages, and 





China has integrated herbal medicines into its primary health care system and is 
exploring new ways to bring the ancient practice of Chinese medicine in line with 
modern standards (Liu and Salmon 2010). The crucial issues relating to the safety 




1.2.4 Regulatory control of herbal medicines in Singapore 
 
In Singapore, there are national regulations on herbal medicines in Singapore. A 
subgroup of herbal remedies is the Chinese proprietary medicines (CPM), which 
is defined as any medicinal product in any dosage form used in the system of 
therapeutics according to the traditional Chinese method (The Statutes of the 
Republic of Singapore, 2005).  
 
The legislations governing the control of CPM in Singapore includes the 
Medicines Act and its subsidiary legislations;  the Poisons Act and its rules; the 
Medicines (Advertisement and Sales) Act and its legislations; and the Sale of 
Drugs Act and its regulations (The Statutes of the Republic of Singapore, 1985a, 
1985b, 1985c, 1999). In future, the regulation of health products, defined as any 
substance, preparation and device intended for use by human principally for 




This will include drugs, medical devices, cosmetics and complementary 
medicines. Currently only medical devices and cosmetics are controlled under the 
Health Products Act. The control of CPM has been implemented since 1 
September 1999 to promote safety and quality of CPM available in Singapore. 
Only products which meet the required standards can be listed by the CPM Unit, 
Health Product Regulation Group, Health Sciences Authority (HSA) and allowed 
to be manufactured, imported, supplied or sold (Yee et al. 2005, Koh and Woo 
2000). 
 
Under the regulatory framework, CPM importers, wholesalers, manufacturers and 
re-packers must be licensed and CPM products assessed by the health authority 
before they are allowed for sale. CPM must comply with the legal permissible 
limits for mercury, arsenic, lead and copper, which are set at 0.5, 5, 20 and 150 
ppm respectively. The microbial contamination is also controlled : total aerobic 
microbial count, no more than 105 per g or ml; yeast and mould count, no more 
than 5 x 102 per g or ml; and Escherichia coli, Salmonellae, Staphylococcus 
aureus, absent in 1 g or ml. Manufacturers or distributors must also ensure that 
CPM is free from prohibited toxic phytochemicals and drug substances controlled 
under the Poisons Act (Chapter 234) (HSA 2011, Yee et al. 2005, Koh and Woo 
2000). 
 
The labels, packaging and package inserts of CPM shall not make references to 




drug addiction, deafness, diabetes, epilepsy or fits, hypertension, insanity, kidney 
diseases, leprosy, menstrual disorders, paralysis, tuberculosis, sexual function, 
infertility, impotency, frigidity and conception and pregnancy) specified in the 
First Schedule to the Medicines Act (HSA 2011, Yee et al. 2005, Koh and Woo 
2000). 
 
There are currently no registration requirements for herbal medicines and none 
are included on a national essential drug list. However, a listing system has been 
established for CPM products. The post-marketing surveillance system for all 
herbal medicines has included adverse-effect monitoring since 1993. There are no 
restrictions on sale of herbal medicines, as long as they comply with the national 





1.3 An Emerging Threat : Adulteration of herbal medicines with PDE-5 
Inhibitors and their related analogues  
 
The market success of the three approved synthetic phosphodiesterase type-5 
(PDE-5) inhibitors for the treatment of erectile dysfunction has led to the 
development of a large market for herbal medicines claimed to be natural 
alternatives to these synthetic drugs. As mandatory requirements regulating the 
manufacture and sale of herbal medicines are much less stringent than those 
related to pharmaceuticals, these herbal sexual enhancement products are heavily 
advertised on the internet and are freely available for purchase without 
prescription. Furthermore, adulteration of these supposedly natural products is a 
very common and serious phenomenon. These adulterated products are usually 
characterized by wildly exaggerated claims and sold to the public by 
unscrupulous manufacturers, without evidence of safety or effectiveness. The 
adulteration has also extended to the analogues of the three approved synthetic 
PDE-5 inhibitors and this is an emerging threat to public safety.  Table 1.2 shows 
the list of reports on herbal health products, claimed to be useful for sexual 
performance enhancement and treatment of erectile dysfunction, that were found 
adulterated with PDE-5 inhibitors, related analogues and other synthetic drug 
substances from the year 2002  based on the literature searches using PubMed and 





As shown in Table 1.2, there is an increase in reports on sexual performance 
enhancement health products adulterated with PDE-5 inhibitors and their related 
analogues over the years. The first PDE-5 inhibitor analogue, homosildenafil was 
reported by Shin in 2003 (Shin et al. 2003) and since then, the list of PDE-5 
inhibitor analogues found in herbal health products continues to grow. Creating 
drug analogues for unregistered use is an old problem. For example, nitroso-
fenfluramine, an analogue of the antiobesity drug, fenfluramine, has been found 
adulterated in slimming supplements resulting in several acute liver injury cases 
and one death each in Singapore and Japan (Adachi et al. 2001, Lau et al. 2004). 
PDE-5 inhibitor analogues are merely new comers. It is believed that adulteration 
of a health product with a drug analogue instead of the parent compound amounts 
to an attempt to evade regulatory inspection. Since analogues are structurally 
modified from the parent drugs, these analogues may escape detection by the 
routine laboratory screening methods. It is important for the regulator to recognize 
this emerging threat so as to introduce effective surveillance system and control 
measures to detect them. 
 
More recently, Venhuis has reported a new analogue, a nitrosated prodrug of the 
PDE-5 inhibitor aildenafil, in a dietary supplement (Venhuis et al. 2011). The 
presence of the nitrosamine moiety may generate nitrite oxide and enhance the 
vasodilating effect of a PDE-5 inhibitor with the risk of a dangerous drop in blood 
pressure (Oliver et al. 2009, Webb et al. 1999). In addition, nitrosamines are also 





It is also worthwhile to note the outbreak of severe hypoglycaemia in 2008 
associated with the consumption of several sexual illegal performance health 
products reported in both Singapore and Hong Kong (Lim et al. 2009, Poon et al. 
2009). A total of 10 deaths and 3 deaths were reported in Singapore and Hong 
Kong respectively.  The presence of glibenclamide in such sexual performance 
enhancement health products was puzzling. It is speculated that glibenclamide 
was wrongly used during the manufacturing process, suggesting the lack of 
stringent good manufacturing practice and inadequate quality control on the part 
of the manufacturer.  
 
The proliferation of the natural sexual enhancement health products, emerging 
threat of adulteration with PDE-5 inhibitors and analogues, and the poor quality 
control by the manufacturers warrant immediate attention and action from health 
authorities in different countries. Prompt education of the public, which must 
include warnings to avoid sexual performance enhancement health products of 
dubious origin will help to reduce the demand of illegal health products. 
Information sharing and co-operation among regulatory bodies will also be 
necessary to trace their ultimate source and eliminate these illegal products. 
Finally, enhancing the testing capabilities of regulatory laboratories in screening 
and structural elucidation of unknown drug adulterants will help in the early 






Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) 
No. Year Adulterants detected Type of herbal products Uses References 
1 2002 Sildenafil Herbal medicine capsules from China Male tonic, sexual 
dysfunction 
Ku et al. 2002 
2 2002 Sildenafil A soft drink collected from Nagoya City (Japan) 
markets by Aichi prefecture drugs inspectors in 2001 
Roborant nutrition Mikami et al. 2002 
3 2002 Sildenafil Pink and cream capsule with dark brown powder 
dietary supplement in Taiwan 
Male tonic, sexual 
dysfunction 
Tseng and Lin 2002 
4 2002 Sildenafil Thirteen herbal medicine samples collected by State 
Food and Drug Administration (SFDA) of China 
Male tonic, sexual 
dysfunction 
Zhang et al. 2002 
5 2003 Homosildenafil An imported miscellaneous beverage submitted for 
inspection in Korea 
Male tonic, sexual 
dysfunction 
Shin et al. 2003 
6 2004 Acetildenafil (a.k.a : 
hongdenafil) 
A commercial herbal drink submitted to Korea Food 
and Drug Administration (KFDA) for testing 
Male tonic, sexual 
dysfunction 
Shin et al. 2004 
7 2004 Acetildenafil, homosildenafil 
and hydroxyhomosildenafil 
Three traditional Chinese medicine samples 
submitted by the Dutch Food and Consumer Product 
safety Authority and Dutch Health Care Inspectorate 
Male tonic, sexual 
dysfunction 
Blok-Tip et al. 2004 
8 2004 Sildenafil, tadalafil and 
homosildenafil 









Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) (Cont.)  
No. Year Adulterants detected Type of botanical health products Uses References 
9 2005 Homosildenafil and 
acetildenafil 
Two dietary supplements in Japan Male tonic Takako et al. 2005 




US FDA 2005  
11 2005 Sildenafil and tadalafil Two herbal products purchased via the internet or at 
Canadian health food stores 
Male tonic, 
treatment of sexual 
dysfunction 
Fleshner et al. 2005 
12 2005 Vardenafil One herbal medicine in oral liquid formulation 
purchased in a supermarket 
Male tonic, sexual 
dysfunction 
Zhu et al. 2005 
13 2006 Acetildenafil A dietary supplement in Taiwan market Treatment of erectile 
dysfunction 
Lai et al. 2006 
14 2006 Hydroxyacetildenafil One dietary supplement submitted to HSA of 
Singapore for testing 
Sexual performance 
enhancement  
Hou et al. 2006 
15 2006 Aminotadalafil and 
hydroxyhomosildenafil 




Zou et al. 2006a 




Pre-mixed bulk powder submitted to HSA of 
Singapore for testing 
Sexual performance 
enhancement  





Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) (Cont.)  
No. Year Adulterants detected Type of botanical health products Uses References 
17 2006 Piperidenafil (a.k.a : 
Pseudovardenafil) 






18 2006 Acetildenafil, homosildenafil 
and hydroxyhomosildenafil 
Two herbal supplements submitted to HAS of 
Singapore for testing 
Sexual performance 
enhancement  
Oh et al. 2006 
19 2006 Sildenafil Herbal supplements purchased by SFDA of China Improving both male 
and female sexual 
function 
Liang et al. 2006 
20 2006 Sildenafil and tadalafil Three marketed herbal products Sexual performance 
enhancement  
Abdel-Hamid 2006 
21 2006 Sildenafil and tadalafil Four herbal products in the market of Saudi Arabia Nourish the body 
and fortify the male 
sexual function 
Bogusz et al. 2006 
22 2006 Aminotadalafil, piperidino 
acetildenafil (a.k.a : 
Piperiacetildenafil), 
hydroxyacetildenafil and 
Piperidino vardenafil (a.k.a : 
Piperidenafil, 
Pseudovardenafil) 
Several “all-natural” herbal products Sexual performance 
enhancement  





Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) (Cont.)  
No. Year Adulterants detected Type of botanical health products Uses References 
23 2006 Sildenafil, 
hydroxyhomosildenafil and 
yohimbine 
Two herbal food supplements in Taiwan market Sexual performance 
enhancement  
Lin et al. 2006 
24 2007 Pseudovardenafil and 
hydroxyacetildenafil 
Two dietary supplement in South Korea market Sexual performance 
enhancement 
Park et al. 2007 
25 2007 Acetildenafil, piperidenafil, 
hydroxyhomosildenafil, 
hydroxyacetildenafil 
Twenty-six dietary supplements bought in Hong 
Kong market 
Male tonic, 
treatment of sexual 
dysfunction 
Poon et al. 2007 
26 2007 Noracetildenafil An herbal dietary supplement submitted to US FDA 
for testing 
Male tonic, 




27 2007 Methisosildenafil (a.k.a : 
Aidenafil) 




Reepmeyer et al. 2007b 
28 2007 Imidazosagatriazinone A dietary supplement in Taiwan market Treatment of  
erectile dysfunction 
Lai et al. 2007a 
29 2007 Piperidenafil (a.k.a : 
Pseudovardenafil) 
A dietary supplement in Taiwan market Treatment of erectile 
dysfunction 
Lai et al. 2007b 
30 2007 Sildenafil Chinese herbal/patent medicines  collected from New 
York City's Chinatown 





Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) (Cont.)  
No. Year Adulterants detected Type of botanical health products Uses References 
31 2007 Desmethylacetildenafil A herbal product Male tonic  Zou et al. 2007 
32 2007 Thiosildenafil, piperidenafil “True Man Sexual Energy”, “Energy Max” Sexual performance 
enhancement  
US FDA 2007 
33 2008 Thioquinapiperifil, 
thiosildenafil 
One dietary supplement in Japan Sexual performance 
enhancement  
Uchiyama et al. 2008 
34 2008 A tadalafil analogue, 
aminotadalafil and 
hydroxyhomosildenafil 
One dietary supplement purchased on the internet Male tonic, 
treatment of sexual 
dysfunction 
Hasegawa et al. 2008 
35 2008 Aminotadalafil and its 
stereoisomers 
A health food in Japan Male tonic  Kurita et al. 2008 




Lam et al. 2008 
37 2008 Thiosildenafil and 
thiohomosildenafil 
Two health supplements submitted to HSA of 
Singapore for analysis 
Sexual performance 
enhancement  
Zou et al. 2008a 
38 2008 Xanthoanthrafil (a.k.a : 
Benzamidenafil) 
A natural herbal supplement sent to HSA of 
Singapore for testing 
Sexual performance 
enhancement  





Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) (Cont.)  
No. Year Adulterants detected Type of botanical health products Uses References 
40 2008 Gendeafil Dietary supplements in Taiwan Energy enforcement Lin et al. 2008 
41 2008 Hydroxyvardenafil and 
methisosildenafil 
A health food seized by KFDA Male tonic  Choi et al. 2008 
42 2008 Homosildenafil and 
thiohomosildenafil 
Marihuana sample in the Netherlands Male tonic  Venhuis and de Kaste 
2008b 
43 2008 Acetildenafil, piperidenafil 
and hydroxyacetildenafil 
Three herbal aphrodisiacs Sexual performance 
enhancement  
Venhuis et al. 2008a 
44 2008 Thiohomosildenafil A herbal aphrodisiac Sexual performance 
enhancement  
Venhuis et al. 2008c 
45 2008 Xanthoanthrafil A dietary supplement in Japanese market Male tonic Kumasaka et al. 2008 
46 2008 Hydroxyhomosildenafil A dietary supplement tested by US FDA Treatment of erectile 
dysfunction 
US FDA 2008 
47 2009 Sildenafil and tadalafil Twenty-five food products and herbal preparations Sexual performance 
enhancement  
Man et al. 2009 





Twenty-six herbal products Sexual performance 
enhancement  




Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) (Cont.)  
No. Year Adulterants detected Type of botanical health products Uses References 
49 2009 Hydroxythiohomosildenafil 
(a.k.a : 
thiohydroxyhomosildenafil) 
Two dietary health supplements bought on-line Sexual performance 
enhancement  
Li et al. 2009a 
50 2009 Dapoxetine A health supplement submitted to HSA of 
Singapore for testing 
Sexual performance 
enhancement  
Li et al. 2009b 
51 2009 Sulfoaildenafil (a.k.a : 
thiomethisosildenafil) 
A bulk material, labeled as an ingredient for a 




Gratz et al. 2009 
52 2009 Sildenafil, tadalafil, vardenafil, 
hydroxyhomosildenafil and 
thiomethisosildenafil 
Seventeen commercial formulations of herbal drugs 
or dietary supplements 
Treatment of sexual 
dysfunction 
Balayssac et al. 2009 
53 2009 Sildenafil and vardenafil Five different cosmetic creams obtained from 
Internet websites 
Treatment of  male 
erectile dysfunction, 
for male and female 
genitals stimulation 
De Orsi et al. 2009 














Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) (Cont.)  
No. Year Adulterants detected Type of botanical health products Uses References 
55 2009 Thiosildenafil and 
thiomethisosildenafil (a.k.a : 
sulfoaildenafil) 
Herbal aphrodisiacs appropriated from distributors’ 
warehouses 
Male tonic, 




56 2009 Cyclopentynafil and N-
Octylnortadalafil 
A dietary supplement in Japanese market Treatment of erectile 
dysfunction 
Hasegawa et al. 2009 




Poon et al. 2009 




Lim et al. 2009   







Hundred and seventy five illegal sexual 
enhancement health products from seven raids 
conducted by HSA of Singapore. 
Sexual performance 
enhancement  
Low et al. 2009 
60 2010 A tadalafil analogue A health food product submitted to HSA of 
Singapore for testing 
Male tonic Haberli et al. 2010  
61 2010 Sildenafil, tadalafil, vardenafil 
and yohimbine 
Twenty-six natural dietary supplements bought at 
Changsha, China 
For male sexual 
health 




Table 1.1  Undeclared synthetic drugs found in herbal products to treat sexual dysfunction or to enhance sexual performance (2002 – 2011) (Cont.)  
No. Year Adulterants detected Type of botanical health products Uses References 




Ng et al. 2010 
63 2010 Hydroxythiohomosildenafil “Magic Power coffee” tested by US FDA Male tonic US FDA 2010c 
64 2010 Sildenafil 85 herbal formulations purchased from different 
cities of India 
Sexual performance 
enhancement  
Savaliya et al. 2010 
65 2011 Acetylvardenafil A dietary supplement, MEGATON, imported from 




Lee et al. 2011 
66 2011 Nitroso-prodenafil A herbal dietary supplement tested by National 
Institute for Public Health and the Environment, 
The Netherlands 







Rationale and Objectives 
 
Herbal remedies promising to enhance sexual performance or for treatment of 
erectile dysfunction have been promoted over the years. These products are 
usually characterized by widely exaggerated claims and sold to the public by 
unscrupulous manufacturers, without evidence of safety and effectiveness. 
Consumers might have been lured into buying them because the social stigma 
attached to their problem makes them shy away from talking to the doctors. Many 
of these products are marketed as health supplements. The mandatory 
requirements regulating the manufacture and sale of these products are much less 
stringent than those related to medicinal products. Adulterated products are less 
commonly found among herbal products classified as Chinese Proprietary 
Medicines (CPM) in Singapore as they require pre-marketing approvals (in the 
form of product listing) and safety assessment which include screening for 
contaminants and adulterants. For health supplements, no pre-marketing approval 
is currently needed.  
 
To protect the safety and health of consumers from the emerging threat of 
adulteration with western drugs and their analogues, more stringent and effective 
control of such high risk herbal products is needed. Health authorities must have 




include the testing of these herbal health products for inherent toxic ingredients, 
contaminants and adulteration.  
 
To enhance the testing capability of herbal medicines in the national quality 
control laboratory, the Health Sciences Authority (HSA) in Singapore has 
collaborated with the Department of Pharmacy, National University of Singapore 
on this study with the objectives to : 
 
(1) assess the quality and safety of sexual enhancement herbal health products 
illegally sold in the red-light districts in Singapore. The assessment will 
create greater public awareness of the danger in consuming such illegal 
health products and hence help to reduce the demand of such products ;   
 
(2) develop a sensitive and rapid LC-Hybrid MS Tandem MS method to 
simultaneously screen for PDE-5 inhibitors and their analogues in sexual 
enhancement herbal supplements. The developed method will help to 
enhance the screening capability of the regulatory laboratory in the 
detection of synthetic PDE-5 inhibitors and their analogues present in 
herbal supplements ; 
 
(3) detect, isolate and structurally elucidate an unknown adulterant in a health 
product claimed for female sexual performance enhancement, which was 




laboratory to develop its capability in structural elucidation of unknown 
adulterants and the findings will allow the regulator to take appropriate 





Safety and quality assessment of 247 illegal sexual  
performance enhancement products seized by Health 




Erectile dysfunction (ED) is a common and important medical condition. Erectile 
dysfunction is defined as the consistent inability to obtain or maintain an erection 
for satisfactory sexual relations. More than 18 million men in United States over 
age 20 are affected by ED (Selvin et al. 2007). The prevalence of ED was strongly 
linked to age, cardiovascular disease, diabetes and a lack of physical activity. The 
U.S. Food and Drug Administration (USFDA) approved phosphodiesterase Type 
5 enzyme (PDE-5) inhibitor drugs to treat ED are Sildenafil (Viagra), Tadalafil 
(Cialis) and Vardenafil (Levitra). Despite the wide use and effectiveness of 
these drugs, clinically significant adverse side effects such as headaches, facial 
flushing and visual disorders, cardiovascular events etc have been reported.  
Habek and Petravić have reported a case with multiple strokes in the posterior 
cerebral circulation in close temporal association with regular sildenafil use 
(Habek and Petravic 2006). Spontaneous post-marketing reports of adverse visual 
events, including nonarteritic anterior ischemic optic neuropathy (NAION) and 




reported (Gorkin et al. 2006, Kontaras et al. 2008, Laties and Sharlip 2006, Laties 
2009, Sobel and Reynolds 2008, Wooltorton 2006). Significant hypotension can 
be found in patients who are concurrently taking nitrates with PDE-5 inhibitor 
(Reffelmann et al. 2008). Associations between sildenafil and neurologic, 
emotional, or psychological disturbances, amnesia or loss of consciousness or 
aggressive behavior have also been reported (Milman and Arnold 2002).      
 
The advent of these highly successfully drugs has spurred the marketing of herbal 
dietary supplements as natural alternatives for the enhancement of sexual 
performance. The growing trend for consumers to turn to natural herbal treatment 
and supplements may be attributed to the assumption that “natural means safe”.  
However, this is not necessarily true. Factors affecting the safety of such products 
include intrinsic toxicity, adulteration, substitution, contamination, 
misidentification, lack of standardization, incorrect preparation and/or dosage and 
inappropriate labeling. Adulteration of health products  with synthetic PDE-5 
inhibitors and their analogues with claims to enhance sexual performance has 
been reported (Blok-Tip et al. 2004, Bogusz et al. 2006, Hasegawa et al. 2009, 
Lam et al. 2008, Oh et al. 2006, Reepmeyer and Woodruff 2006, Shin et al. 2003, 
Zou et al. 2006a, Zou et al. 2008a). More recently, four illegal sexual performance 
enhancement products have been reported to be adulterated with sildenafil and a 
very high dose of glibenclamide (HSA 2008b). These products have caused severe 





In this study, we report the findings on the screening of 247 illegal sexual 
enhancement health products for western drug adulterants.  These products are 
claimed to be natural supplements for enhancement of sexual performance and 
they were seized by Health Sciences Authority from make-shift stalls at the red-
light district areas in Singapore and Singapore Customs during the period 





The objective of this work is to evaluate the extent of adulteration of health 
products with synthetic PDE-5 inhibitors and other drugs, and the risks of 







All chemicals used were analytical grade or better. Acetonitrile and methanol 
(HPLC grade) were purchased from LAB-SCAN. Water for HPLC was treated 
with a PURELAB Ultra water purification system (ELGA). Sildenafil citrate, 




TLC PharmaChem., Inc. (Vaughan, Ontario Canada). Tadalafil was supplied by 
Eli Lilly Company (Indianapolis, IN, USA). Vardenafil hydrochloride was 
supplied by Bayer Corporation (West Haven, CT, USA). Lignocaine was supplied 
by Sigma (Sigma-Aldrich, USA). Sibutramine hydrochloride monohydrate was 
supplied by Abbott Laboratories (Abbott Park, Illinois, USA). Chloramphenicol, 
glibenclamide and naproxen were supplied by United State Pharmacopeia (USP, 
Rockville, USA).  
 
3.3.2 Samples and standards  preparation 
 
A total of 247 illegal sexual performance enhancement health products that were 
claimed to be natural supplements for the enhancement of sexual performance 
were seized by Health Sciences Authority from 7 major raids that involved 17 
make-shift stalls at the red-light districts in Singapore and a shipment to 
Singapore through Singapore Customs during the period February to December 
2008. The products were screened for the presence of western drug adulterants. 
 
For sample preparation, 10 ml of methanol was added to 1 g of the powdered 
sample. For liquid sample, 1 g of the liquid was diluted with 10 ml of methanol. 
The powdered or diluted sample was sonicated for 10 minutes and filtered 
through 0.45 m membrane filter for preliminary screening by reversed phase 
high-performance liquid chromatography (HPLC-DAD) and gas chromatography-




libraries, namely Wiley7 (John Wiley & Sons Pte Ltd., United States) and Nist05 
(National Institute of Standards and Technology, United States).   
 
Confirmation of adulterants was performed by liquid chromatography tandem 
mass spectrometry (LC-ESI-MS/MS). The sonicated sample was further diluted 
from 10 to 1000 times with methanol, depending on the concentration level of the 
adulterants and filtered through 0.45 m membrane filter for direct injection.  
 
Quantitative analysis was performed using the above high-performance liquid 
chromatography (HPLC-DAD) system. 10 ml of methanol was directly added to 
about 0.25 g of the homogenized powdered or liquid sample. The powdered or 
diluted sample was sonicated for 10 minutes and filtered through 0.45 m 
membrane filter for quantitation analysis. Standard solutions (0.0125 mg/ml, 
0.025 mg/ml, 0.05 mg/ml, 0.125 mg/ml and 0.25 mg/ml) of the adulterants 
detected were prepared for calibration purposes. Further dilution was performed 
for those adulterants detected at higher concentrations than their respective 
standard calibration range.   
 
3.3.3 Screening by HPLC-DAD  
 
A Hewlett Packard (HP) series 1100 quaternary gradient pump, photo-diode array 
detector and HP series 1100 autosampler (Palo Alto, CA, USA) were used. 




performed with an in-house ultraviolet spectra library using HP ChemStation 
software for LC 3D. A BDS Hypersil reverse phase (RP) C18 200 x 4.6 mm x 5 
m column from Thermo Scientific, United States, was used. 
 
Gradient elution (acetonitrile/phosphate buffer) was performed as follows: 
Solvent A - sodium dihydrogen phosphate buffer (25 mM, pH 3.2) ; Solvent B – 
acetonitrile ; step gradient is from 10% to 30% v/v of B over 10 min, then to 50% 
of B over another 10 min and finally to 70% v/v of B over 10 min and maintained 
for 5 min. Total chromatographic duration was 35 min. The equilibration time 
between two consecutive injections was set at 5 min (total cycle time 40 min). 
The flow-rate of the mobile phase was 1 ml/min. Injection volume was 10 l. The 
detection wavelengths were set at 220, 254 and 280 nm. The UV spectra from 200 
to 400 nm were recorded on-line during the chromatographic run.  
 
A HSA in-house ultraviolet (UV) spectra library of 420 drug substances was used 
for the screening test. An autolibrary search for adulterants was conducted. 
Unknown UV spectra were compared with those UV spectra in the UV spectra 
library. A library match score of 1000 represents a perfect match.     
 
3.3.4 Screening by GC-MS  
 
HP 6890 series of GC system fitted with HP 6890 series injection and HP 5973 




The analytes were separated with a HP-5 MS capillary column (5% phenyl-95% 
methyl siloxane; 25 m x 0.2 mm internal diameter capillary) with the carrier gas 
(helium) set at 1 ml min -1. A 1.0 µl volume of the sample was injected using the 
splitless mode. The data acquisition system was controlled by MS ChemStation. 
Full scan mass spectra were collected between 50 and 550 amu at 1.53 scan s-1. 
The MS was operated in the electrospray ionization mode. The initial oven 
temperature was set at 800C. It was then increased to 3000C at 100C min-1. The 
final temperature of 3000C was held for 10 min. The total running time was 32 
min. The Wiley standard chemical MS library (McLafferty et al. 1998) and 
spectra of reference standards were used in the drug identification. 
 
3.3.5 Confirmation by LC-ESI-MS/MS  
 
Confirmation of the adulterants in the samples was performed by the use of LC-
ESI-MS/MS. An API 2000 Triple Quadrupole LC/MS/MS mass spectrometer 
from MDS Sciex/Applied Biosystems (Foster City, CA, USA) coupled to a 
Shimadzu LC system (LC-10ADVP, Nakayo-ku, Japan) was used. Data 
acquisition and processing were performed using the Analyst software from 
Applied Biosystems (Foster City, CA, USA). Separation was carried out using a 
BDS Hypersil C18 reversed-phase column (150 mm x 2.1 mm I.D, 5 m). 
Gradient elution was performed as follows : Solvent A – 0.1% formic acid in 
water ; Solvent B – acetonitrile ; step gradient was from 20% to 95% of B over 5 




of the mobile phase was 0.25 ml/min. The injection volume was 10 L. The mass 
spectrometer was coupled with the LC system in splitless mode. An electrospray 
ionization interface with positive mode was employed. The ESI conditions were 
as follows : declustering potential, 65 V; focus potential, 400V; entrance potential, 
10.0 V; curtain gas, 40 (arbitrary units); collision gas, 7 (arbitrary units) ; ion 
spray voltage, 4.5 kV; source temperature, 350 0C; ion source gas 1, 40 (arbitrary 
units); ion source gas 2, 60 (arbitrary units); and MS full scan range : m/z 50-550. 
Both quadrupoles were maintained at unit resolution. For MS2 run, collision 
energy was set at 50 V for all analyses.   
 
3.3.6 Quantification by LC-DAD   
 
Quantitative analysis was conducted using the above LC-DAD and conditions for 
all adulterants accept for the analogues of PDE-5 inhibitors (piperidenafil, acetil 
acid, sulfosildenafil and sulfohomosildenafil). The detector was set at 254 nm.   
 
The previously reported and validated methods (Liu et al. 2001) were used with 





3.4 Results and Discussion 
 
3.4.1 Safety Assessment 
 
Details of the 247 illegal health products and the chemical analysis results are 
presented in Appendix I. 
  
The results showed that 190 samples (76.9%) were adulterated with western drugs 
or their analogues. Among the 190 samples found to contain western drug 
adulterants, 150 samples contained only 1 adulterant while 40 samples contained 
more than 1 adulterant. A majority of these samples (165, 86.8%) were found to 
be adulterated with sildenafil. 22 samples were adulterated with tadalafil (11.6%). 
3 samples were found to be adulterated with vardenafil (1.6%) and 42 samples 
contained other adulterants (22.1%).  In addition, 4 analogues of PDE-5 inhibitors 
were also detected. They were piperidenafil, acetil acid, thiosildenafil and 
thiohomosildenafil.  Figure 3.1 summarized the adulterants detected in the 190 
adulterated samples. Six counterfeit drugs of the 3 approved PDE-5 inhibitors, 
Cialis, Levitra and Viagra in different dosage forms and batches had also been 
seized and screened for adulterants. Sildenafil was detected in all of these 
products. Increasing, the counterfeit product labelled as “Cialis Tadalafil 80 mg” 
was not found to contain tadalafil. No vardenafil was detected in the products 





92 samples (55.8%) of the products adulterated with sildenafil were found to 
contain more than 100 mg per dosage unit of sildenafil (Figure 3.2). The 
therapeutic dosage of sildenafil, Viagra (Pfizer), for erectile dysfunction is 25 
mg to 100 mg taken not more than once per day.  Two products, namely “Power 1 
Walnut 动力一号核桃素片” (product number 135 in Appendix 1) and “Zhong 
Hua Niu Bian 中華牛鞭” (product number 244 in Appendix 1) were found to 
contain high doses of glibenclamide, 98.9 mg per tablet and 13.1 mg per capsule 
respectively. In addition, 11 of the products (5.8%) were found to contain trace 
amounts of sibutramine.  
 
3.4.2 Product labels and claims 
 
Twenty of the products screened are targeted for female consumers. Among these 
products, 3 (15%) were found to contain lignocaine. Unlike those for male 
consumers, most of these products (13/20, 65%) are in solution or cream form.  
Many products are claimed to be extracts of natural herbs or are produced by 
modern techniques. Many did not state their manufacturing dates. Most of them 
have simple labels with indications, side effects and dosage. No information on 
drug interactions and toxicity is provided. Only a few products bear information 
to advise consumers to consult with a physician before taking the products and 
some of them offer “antidotes” for side effects: drinking a large volume of cold 
water. Many products are labelled to be safe for consumers with heart diseases, 



































































































Figure 3.1  No. of times (with percentage) that each adulterant was detected in the 190 samples that were found to be 














































The easy accessibility and lower pricing of the sildenafil raw material from illegal 
sources may be one of the reasons for the high incidence of adulteration with 
sildenafil. Tadalafil and vardenafil were comparatively less encountered as an 
adulterant in such illegal health products. Sildenafil, tadalafil and vardenafil are 
inhibitors of PDE-5 and are used as oral therapy for erectile dysfunction 
(Sweetman 2007). These drugs are rapidly absorbed after oral dose. Peak plasma 
concentrations are attained within 30 – 120 minutes for sildenafil and vardenafil 
Figure 3.2  Levels of sildenafil detected per dosage unit in the 165 products that 






and within 2 hours for tadalafil. The terminal half-lives of sildenafil and 
vardenafil are about 4 – 5 hours while the mean half –life of tadalafil is about 17.5 
hours (Sweetman 2007). The much shorter time required to attain peak plasma 
concentrations may be the reason for the preference of sildenafil over tadalafil as 
adulterant in illegal health products. In this study, 6 counterfeit products of 
approved PDE-5 inhibitor drugs were detected. Such counterfeit drugs are poor in 
quality with ingredients that are different from their label claims. 
 
The presence of prescription drugs in such products posed severe risk to consumer.  
Consumers taking nitrate medications for hypertension, hyperlipidemia and 
ischemic heart diseases may experience drastic drop in blood pressure if they 
consume such illegal health products adulterated with the synthetic PDE-5 
inhibitors (Gorkin et al. 2006, Habek and Petravic 2006, Kontaras et al. 2008, 
Laties and Sharlip 2006, Laties  2009, Milman and Arnold 2002, Nencini et al. 
2008, Sobel and Reynolds 2008, Wooltorton 2006). In addition, the high 
concentration of sildenafil (more than 100 mg per dosage unit) in about half of the 
illegal health products adulterated with sildenafil is believed to be the approach 
taken by dishonest manufacturers to ensure the efficacy of the products.  However, 
an overdose of sildenafil and its misuse can be dangerous in view of the various 
adverse events reported 
 
More alarmingly, the presence of glibenclamide in high doses is puzzling as well 






therapeutic dose of 2.5 – 20 mg for daily treatment of diabetes (Sweetman 2007). 
Glibenclamide is a sulfonylurea antidiabetic drug. Glibenclamide is readily 
absorbed from gastrointestinal tract, with peak plasma concentrations usually 
occurring within 2 to 4 hours, and it is extensively bound to plasma proteins. 
Glibenclamide has a relatively long duration of action of up to 24 hours and 
appears to cause severe hypoglycaemia more often than shorter-acting 
sulfonylureas such as tolbutamide (Sweetman 2007). These 2 products were 
responsible for the severe hypoglycaemia cases leading to 10 deaths in Singapore 
as at 30 Oct 2008 (HSA 2008c). Pharmacologically, glibenclamide is not known 
to improve sexual performance and based on the batch number of the adulterated 
product, Power 1 Walnut 动力一号核桃素片, together with the period of adverse 
drug reaction reporting, there is a possibility that glibenclamide was wrongly used 
during the manufacturing process in Jan 2008. From our analyses, previous 
batches of “Power 1 Walnut 动力一号核桃素片” manufactured prior to the year 
2008 were free from glibenclamide. The drug adulteration resulted in fatality and 
is likely to be a result of the lack of stringent GMP. GMP prohibits any changes 
of formulation according to the free will of the manufacturer. Inadequate quality 
control of the health products will definitely be associated with high incidence of 
health risks when these products are consumed on a regular basis (Low et.ah 
2010).  
 
With regards to product label claims, many of them are incorrect, misleading and 






consequences of posting potential danger to the consumers and it is important for 
National Authorities to collaborate/work together to curb the supply sources. One 
limitation is that the manufacturers on the labels often do not exist. 
The presence of lignocaine in female consumer products, largely topical 
preparations for vaginal use, may be explained by lignocaine’s local anaesthetic 
effect to relieve pain, burning and itchy sensations during sexual intercourse. 
 
For products that were seized from the raids in red light districts, they were 
openly presented for sale at make-shift stalls.  After a couple of raids, the 
operators started hiding the products along drains, in beer carton boxes etc while 
some chose to display empty product boxes instead.  Some products were hidden 
in motorcycles and were only retrieved for sale when there were interested 
customers. The 247 illegal sexual enhancement products were seized from 7 
major raids in red light districts and a shipment to Singapore through Singapore 
Customs. Such illegal sexual enhancement products are available worldwide and 
it is important to alert potential consumers, health professionals and regulators of 
the possibility of adulteration, counterfeiting and presence of high levels of 
sildenafil and glibenclamide.  
 
The data in this report in general may be affected by the narrow region where 
products were seized - all within the red-light district areas in Singapore and 






wide survey may give different results e.g. perhaps not such a domination of 






In conclusion, 190 (77%) illegal health products out of 247 products for sexual 
performance enhancement and treatment of erectile dysfunction seized from red-
light district areas in Singapore and shipments to Singapore through the Singapore 
Customs were found to be adulterated with western drugs and their analogues.   
 
The extent of the adulteration in part explained the effectiveness of these illegal 
health products in sexual performance enhancement.  Hence, with the low price 
and efficacy, the demand of these products remains high, despite the many severe 
and sometimes fatal cases of adverse drug reactions reported. It is conceivable 
that such illegal sexual enhancement products might work in showing their 
effectiveness of sexual enhancement on the principle of the adulterated drug, and 
not so on the pharmacognostic nature of the natural herbs. Besides, in the 
presence of a readily available source with affordable price, the adulterated drug 
can easily be manipulated in multiple health product manufacturing, which 
ultimately cause severe and sometimes fatal cases of adverse drug reactions so 






To safeguard public health, greater public awareness of the danger of consuming 
such illegal products and the lack of quality control of these illegal sexual 
performance enhancement health products, is important. An effective public 
education programme will help to reduce the demand of such illegal health 
products and complement the enforcement actions taken in the control of the 
supply of such illegal health products in the market. Healthcare professionals, 
regulators and the media play an important role in effective public education, 







Screening of PDE-5 Inhibitors and their analogues in 
sexual performance enhancement health products by 





Sildenafil (Viagra; Pfizer, NY, USA), tadalafil (Cialis; Elli Lilly, IN, USA) and 
vardenafil (Levitra; Bayer Pharmaceuticals Co., Wuppertal, Germany) are three 
phosphodiesterase-5 (PDE-5) inhibitors licensed for the treatment of erectile 
dysfunction (ED) (Gratz et al. 2004). The prevalence of erectile dysfunction, high 
cost of treatment, sensitivity of the condition, presence of side effects, adverse 
events and the requirement for medical supervision of the therapy have led to the 
promotion of herbal supplements as substitutes in enhancing male sexual function, 
often under the premise that natural products are safer. While there are many such 
herbal products sold at local stores or over the internet which claim to enhance 
sexual performance, there have been reports of some “natural” products with 
synthetic PDE-5 inhibitors and their analogues (Haberli et al. 2010, Lee et al. 
2011, Ng et al. 2010, Savaliya et al. 2010, US FDA 2010c, Venhuis et al. 2011, 
Zhang et al. 2010). Manufacturers of these products usually claimed that the 






safety of these adulterated products has not been clinically tested and may cause 
unpredictable health effects on consumers. The challenge for the drug regulatory 
control agencies to effectively assess and regulate such adulterated products is to 
have a robust, high-throughput, sensitive and reliable test method to 
simultaneously screen for the synthetic PDE-5 inhibitors and their analogues 
adulterated in such herbal supplements. 
 
Since 2004, there were reports of LC-MS and LC-MS-MS screening methods for 
simultaneous detection of the 3 approved PDE-5 inhibitors, namely sildenafil, 
tadalafil and vardenafil (Abdel-Hamid 2006, Gratz et al. 2004, Savaliya et al. 
2009, Zhang et al. 2010, Zhu et al. 2005). With the emerging threat from 
analogues of PDE-5 inhibitors, four screening methods were reported to 
simultaneously detect the PDE-5 inhibitors and their related analogues. However, 
these methods are restricted to only a few analogues. Zou et al. has  developed a 
LC-ESI-MS/MS method for simultaneous detection of the sildenafil, vardenafil, 
tadalafil and three related analogues (homosildenafil, hydroxyhomosildenafil and 
acetildenafil) (Zou et al. 2006b). Balayssac et al. has developed a 2D and 3D 
DOSY 1H NMR method to screen for sildenafil, tadalafil, vardenafil and three 
related analogues (hydroxyhomosildenafil, thiosildenafil and 
thiomethisosildenafil) (Balayssac et al. 2009).  Gryniewicz et al. has developed an 
ion mobility spectrometry (IMS) method to screen for sildenafil, tadalafil, 
vardenafil and five related analogues (methisosildenafil, homosildenafil, 






Ng et al. has developed an LC-MS-MS screening method based on precursor ion 
scan to specifically detect analogues of sildenafil, vardenafil and acetildenafil (Ng 
et al. 2010). This method is however limited to analogues that have the same 
selected precursor ions for sildenafil, vardenafil and acetildenafil.   
 
In this study, a LC-Hybrid Tandem MS method was developed to simultaneously 
screen for a total of 25 PDE-5 inhibitors and related analogues in a single run of 
20 minutes. Samples were extracted by methanol and directly screened by the 
system. A multiple reaction monitoring (MRM) as survey scan and an enhanced 
product ion (EPI) scan as dependent scan were performed in an information-
dependent acquisition (IDA) experiment. Finally, drug identification was carried 
out by library search with a newly developed MS/MS library based on EPI spectra 
at 3 different collision energies in positive ionization mode. To the best of our 
knowledge, this is thus far the only method that can provide such comprehensive 





The objective of this study is to develop a LC-Hybrid Tandem MS method to 











All chemicals used were analytical grade or better. Acetonitrile and methanol 
(HPLC grade) were purchased from LAB-SCAN. Water for HPLC was treated 
with a PURELAB Ultra water purification system (ELGA).  Sildenafil citrate, 
were supplied by TLC PharmaChem., Inc. (Vaughan, Ontario Canada), tadalafil 
was supplied by Eli Lilly Company (Indianapolis, IN, USA) and vardenafil 
hydrochloride was supplied by Bayer Corporation (West Haven, CT, USA). The 
other 22 PDE-5 inhibitors analogues reference standards (acetil-acid,  
acetildenafil, aminotadalafil, carbodenafil, chloropretadalafil, dimethylsildenafil, 
gendenafil, homosildenafil, hydroxyacetildenafil, hydroxyhomosildenafil, 
hydroxythiohomosildenafil, imidazosagatriazinone, N-desethylacetildenafil, N-
desmethylsildenafil, normeosildenafil, piperiacetildenafil, thiodimethylsildenafil, 
thiohomosildenafil, thiosildenafil, udenafil and xanthoanthrafil) were synthesized 
by TLC PharmaChem., Inc. (Vaughan, Ontario Canada) for this study.  
 
4.3.2 Sample preparation for validation  
 
Eleven validation samples, which were previously tested by HSA, were supplied 
by HSA and chosen by A/P Koh out of 140 samples as blind samples for the 






which were not made known to the analyst prior to the validation, were 
summarized in Table 4.1. 1 g samples were extracted by 10 ml methanol. The 
extraction samples were further diluted 500-fold with methanol. The diluted 
sample solutions were directly screened by the LC-Hybrid Tandem MS System. 
For cases that showed overloaded signals, the diluted sample solutions were 
further diluted 20-fold and re-screened by the LC-Hybrid Tandem MS System. 
 
The limit of detection (LOD) for the 25 PDE-5 inhibitors and analogues were 
determined based on 3 times the signal-to-noise ratio through the injection of their 
respective 50 ppb standard solutions.  
 
4.3.3 Instrumentation and chromatographic conditions for screening test 
 
The HPLC analysis was performed with an autosampler, column oven and a 
binary pump (HP1200 series LC, Agilent, Waldbrown, Germany). For the 
separation, an Dionex Acclaim® 120 C18 RP analytical column (2.1mm x 
150mm, 3µm) was used. A gradient starting with 20% mobile phase B 
(acetonitrile with 0.1% formic acid (v/v) and 0.1% ammonium formate (v/v) was 
increased linearly to 80% B over 10 min, kept constant at 80% B for 5 min, and 
then decreased to 20% B in 0.5 min and re-equilibrated for 5 min.  Mobile phase 
A consisted of aqueous solution containing 0.1% formic acid (v/v) and 0.1% 
ammonium formate (v/v). The flow rate was 0.3 ml/min, injection volume was 5 







For the MS/MS screening, an API QTrap4000 with Cliquid™ Software and a 
TurboIonSpray source (Applied Biosystems, Ontario, Canada) was used. Infusion 
of reference standards of the 25 PDE-5 inhibitors and analogues was performed to 
identify the MRM transition parameters (Q1 and Q3 at optimized DP, EP, CE, 
CXP). TEM was set at 5000C with a curtain gas 20psi, nitrogen collision gas 
(CAD) set to high, GS1 40 psi and GS2 70 psi. The current was 4KV with the 
interface heater on. The declustering potential (DP), entrance potential (EP), 
collision energy (CE) and collision cell exit potential (CXP) were optimized for 
each of the 25 PDE-5 inhibitors and analogues. The survey scan containing 25 
MRM transitions for the 25 PDE-5 inhibitors and analogues was summarized in 
Table 4.2. Each transition was performed with a 50 ms dwell time and a pause 
time of 2 ms at the optimized CE. Total scan time was 1.3 s for all 25 transitions.  
 
The IDA scan intensity threshold was set to 1000 counts per second (cps). The 
dependent scan was an EPI scan, which was carried out at 3 different CEs : 20, 35 
and  50 eV. Fill time of the trap (Q3) was set to 50 ms, linear ion trapping (LIT) 
scan rate was 4000 amu/s. Three EPI scans were performed before switching back 
to MRM mode.  The maximum cycle time (MRM + three EPI scans) was 3.4s. 
Dynamic exclusion, which defines the time for which a transition is excluded 
after acquiring an EPI scan, was set to 18s to allow the detection of coeluting 
substances. The resulting EPI spectra were then searched against the newly 







4.3.4 MS/MS library 
 
The MS/MS library was developed based on the EPI spectra of the 25 PDE-5 
inhibitors and related analogues reference standards at three different CEs (20, 35 
and 50 eV) in positive ionization mode. The concentration of the reference 
standards used was 50 ppb.  Mass tolerance and purity threshold for library search 
were set at 0.50 and 10%.  
 
4.3.5 Confirmation of adulterants  
 
Confirmation test was performed to ascertain the presence of those adulterants 
suggested by the library of the screening system developed. Confirmation was 
performed by injecting the reference standards of the suspect adulterants (at 
concentration similar to the unknown) into the same the LC-Hybrid Tandem MS 
Screening System. The retention times (RT) and EPI spectra of the reference 
standards of the suspect adulterants were compared against the retention time (RT) 











Description Batch Number Manufacture Dosage Form Ingredients/quantity 
Adulterant 
Detected 






2 Wei Ge 99 偉哥 99  Q/LZB-003-2003 西藏拉萨市力龙生物制品公司 





3 Wei Bao Capsules  胃 宝 胶 囊 B102 Yi Shi Yuan Pte Ltd 
Transparent 
capsule with light 
brown powder 
Cortex Cinnamomi, Fructus 
Amomi Rotundus, Fructus 
Amomi, Rhizoma Pinelliae 
Praeparata, Herba Menthae, 
Pericarpium Citri Retiiculatae, 
Radix Aucklandiae, Radix Et 
Rhizome Glycyrrhizae, Rhizoma 
Cyperi, Flos Caryophylli, Fructus 
Aurantii Praeparata, Endoconche 
Sepine, Pericarpium Zanthoyli 
ND 
4 Qiang Li Wei Ge Wang 强力威哥王   - - 
Blue tablet with 




Liu Wei Di Huang 
Jiao Nang  
六 味 地 黄 胶 囊 
BD1902090112 SingCo Pharma Pte Ltd 
Bright blue/light 
blue capsule with 
brown powder 
Radix Rehmanniae Praeparata, 
Cortex Moutan, Poria, Fructus 
Corni, Rhizoma Dioscoreae, 
Rhizoma Alismatis, Tartrazine 
ND 










Table 4.1    Details of the eleven blind samples for validation study (Cont.) 
Sample 
Code Product Description Batch Number Manufacture Dosage Form Ingredients/quantity 
Adulterant 
Detected 
7 Zeng Ye Jiao Nang  增 液 胶 囊 DB1212081111 SingCo Pharma Pte Ltd 
Purple/black capsule 







8 Nan Gen Jing Hua Su  男根精华素 - 香港金黄金科技开发有限公司 






9 XTRABIG - Incontech Pte Ltd Red capsules - Dimethylsildenafil, Thiodimethylsildenafil  
10 San Ti Niu Bian Bo Dong Li 三體牛鞭勃动力 Q/WS9-95 安徽三体医药保健品公司 
Blue and white 








Refine Yin Qiao For Cold 
Capsules (Concentrated) 
精 制 银 翘  
E903T Union Chemical & Pharmaceutical Pte Ltd  
Dark green/light 
green capsule with 
brown powder 
Flos Lonicerrae, Fructus 
Forsythiae, Radix 















Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues   





































































Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues  (Cont.)  

















































































Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues  (Cont.)  


































































































Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues  (Cont.)  












































































































Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues  (Cont.)  











































































Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues  (Cont.)  








































































Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues  (Cont.)  











































































Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues  (Cont.)  





























































































Table 4.2  MRM transitions, infusion data and LOD for PDE-5 inhibitors and their related analogues  (Cont.)  


















































DP Declustering potential CE Collision energy  EP Entrance potential CXP Collision cell exit potential    







4.4 Results and discussion 
 
The analytical procedure is summarized in Figure 4.1. The developed method was 
successfully applied to the 11 validation samples which were obtained from the 
HSA investigative cases and selected by A/P Koh.  Dynamic exclusion of 
detected MRM transition was used to detect coeluting compounds. This is 
especially important for adulteration cases, where unknown analogues with 



















a given threshold 
of 1000 cps 
Survey scan 
(MRM for 25 PDE-5 Inhibitors and their analogues) 
Dependant scan 
EPI with 3 CEs : +20 eV, +35 eV, +50 eV  
Dynamic 
exclusion 
time 18 s  
Library search 







Figure 4.2 shows the total ion chromatogram of the extracted validation sample 
No. 6 whereby aminotadalafil, an analogue of tadalafil, was detected. A typical 
library search result in this case for validation sample No.6, is as shown in Figure 
4.3. The purity is a measure of the similarity of the library spectrum and the 
unknown spectrum and it falls in the range 0 to 100 (Stein and Jordon 1994).  
 
TIC of +MRM (26 pairs): Exp 1, from Sample 1 (Spl 6) of 2010_07_12_183436_PDE 5 Inhibitors_3 CE_Posi_DFT_0012.wiff (Turbo Spra... Max. 5.1e5 cps.













































Retention Time:  7.24 minutes     Q1/Q3: 391.4/269.1 amu     Area: 127000 counts Date: 7/12/2010 11:04:41 PM



















 Compound Name Purity 
(%) 
Compound Name Purity 
(%) 
Compound Name Purity 
(%) 





Figure 4.3   Library search results for validation sample no. 6 - acquired analyte sprectra and library spectra at CE (a) 20 eV, (b) 35 eV and (c) 50 eV 






The LOD of the 25 PDE-5 inhibitors and related analogues based on 3 times the 
sign-to-noise ratio (ICH 1996) are summarized in Table 4.2. 
 
The validation results are summarized in Table 4.3. The validation results were 
compared to the HSA previous testing results obtained by LC-DAD screening. 
The developed LC-Hybrid Tandem MS screening method was able to pick up all 
the PDE-5 inhibitors and analogues adulterated in these validation samples except 
for the trace piperidenafil in Sample 1. The purity match for the positive detection 
at the 3 CEs ranged from 68.2% to 100.00% for all positive adulterants detected 
except for tadalafil in sample 4, which has a library purity match of 30.7% at CE 
50. This was attributed to the matrix interferences from this sample at CE 50, 
which resulted in low purity match.  
 
For sample 1, trace amount of piperidenafil was previously detected by HSA 
using LC-DAD screening method. However, for the LC-Hybrid Tandem MS 
screening system developed, the sample injected to the system is 500 times more 
dilute than the LC-DAD screening method, in view of the high sensitivity of the 
LC-Hybrid Tandem MS screening system. Piperidenafil, which is present in trace 
amount, was not detected after such a dilution. On the other hand, traces of 
homosildenafil was detected by the new LC-Hybrid Tandem MS screening 
method and was not detected previously by the LC-DAD screening method. The 
HSA LC-DAD screening system was unable to detect traces of homosildenafil as 






However, in the LC-Hybrid Tandem MS system, the trace homosildenafil was 
detected as the mass pairs for sildenafil and homosildenafil are different. This 
demonstrates the usefulness of the selectivity and specificity of the LC-Hybrid 
Tandem MS method developed. 
 
For sample 4, trace amount of vardenafil was detected by the LC-Hybrid Tandem 
MS screening system. The method is more sensitive in detecting vardenafil 
compared to the LC-DAD screening system. 
 
The validation study revealed some discrepancies in both screening results (LC-
Hybrid Tandem MS and LC-DAD) for trace contaminants. This is attributed to 
the difference in the detection sensitivity of these methods towards the trace 
contaminants. As the targeted analytes for adulterants screening are usually 
present at therapeutic level, it is advisable to retain the sample preparation of this 
study (i.e. 1 g sample to be extracted by 10 ml methanol, follow by 500 times 
dilution with methanol). Without the 500 times dilution step, there is a risk of 
system overload and contamination by the main adulterants, which are usually 
present in large quantities. In addition, severe mass shift due to overloaded signal 
contributed by the main adulterants may be experienced and this will affect the 
detection of the adulterants through library search and match.  In general, the LC-
Hybrid MS screening method is rapid, selective and capable of simultaneous 












Library Search Result 
Confirmation 
Result Remark 
CE 20 CE 35 CE 50 
Suggestion RT (Std) Purity Suggestion 
RT 





Homosildenafil 6.16 98.00 Homosildenafil 6.16 92.90 Vardenafil 5.26 82.40 
Vardenafil 
Same finding as HSA 
except for piperidenafil in 
trace was not detected. 
Additional adulterant, 
homosildenafil was 
detected in trace amount, 
as a result of the higher 
sensitivity of the LC-
Tandem MS screening 
system.  
Dimethylsildenafil 6.29 97.80 Dimethylsildenafil 6.29 74.80 Homosildenafil 6.16 31.80 
Vardenafil 5.26 93.50 Vardenafil 5.26 74.80 Dimethylsildenafil 6.29 26.50 
5.96 Sildenafil 6.00 100.00 Sildenafil 6.00 100.00 Sildenafil 6.00 89.30 Sildenafil 
6.08 
Dimethylsildenafil 6.29 100.00 Dimethylsildenafil 6.29 90.40 Homosildenafil 6.16 70.30 
Homosildenafil  Homosildenafil 6.16 100.00 Vardenafil 5.26 90.40 Dimethylsildenafil 6.29 58.10 
Vardenafil 5.26 96.00 Homosildenafil 6.16 86.70 Vardenafil 5.26 57.00 
2 5.94 Sildenafil 6.00 100.00 Sildenafil 6.00 100.00 Sildenafil 6.00 89.30 Sildenafil Same finding as HSA. 
3 Nil                   Nil Sample not adulterated. Same finding as HSA. 
4 
5.13 
Homosildenafil 6.16 100.00 Dimethylsildenafil 6.29 100.00 Vardenafil 5.26 86.50 
Vardenafil Same finding as HSA. 
Trace vardenafil was 
detected by LC-Hybrid 
Tandem MS system but 
not in HSA LC/DAD 
system. 
Vardenafil 5.26 99.30 Vardenafil 5.26 100.00 Homosildenafil 6.16 39.40 
Dimethylsildenafil 6.29 84.30 Homosildenafil 6.16 95.60 Dimethylsildenafil 6.29 25.60 
5.96 Sildenafil 6.00 84.80 Sildenafil 6.00 100.00 Sildenafil 6.00 89.90 Sildenafil 











Library Search Result 
Confirmation Result Remark CE 20 CE 35 CE 50 
Suggestion RT (Std) Purity Suggestion 
RT 
(Std) Purity Suggestion 
RT 
(Std) Purity 
5 Nil                   Nil 
Sample not 
adulterated. Same 
finding as HSA. 
6 7.24 Aminotadalafil 7.24 94.30 Aminotadalafil 7.24 83.70 Aminotadalafil 7.24 74.30 Aminotadalafil Same finding as HSA. 
7 Nil                   Nil 
Sample not 
adulterated. Same 
finding as HSA. 
8 5.94 Sildenafil 6.00 92.40 Sildenafil 6.00 95.30 Sildenafil 6.00 89.70 Sildenafil Same finding as HSA. 
9 
6.26 
Dimethylsildenafil 6.29 100.00 Dimethylsildenafil 6.29 68.20 Dimethylsildenafil 6.29 83.00 
Dimethylsildenafil 
Same finding as HSA. 
Homosildenafil 6.16 100.00 Vardenafil 5.26 68.20 Homosildenafil 6.16 68.20 
Vardenafil 5.26 97.80 Homosildenafil 6.16 63.90 Dimethylsildenafil 6.29 66.60 
            Vardenafil 5.26 22.90 
8.26 
Thiohomosildenafil 8.29 94.80 Thiohomosildenafil 8.29 96.80 Thiohomosildenafil 8.29 66.80 
Thiodimethylsildenafil 
Hydroxyvardenafil 4.99 94.80 Hydroxyvardenafil 4.99 96.80 Hydroxyvardenafil 4.99 18.70 
Thiodimethylsildenafil 8.60 94.80 Thiodimethylsildenafil 8.60 96.80 Thiodimethylsildenafil 8.60 80.70 











Library Search Result 
Confirmation Result Remark 
CE 20 CE 35 CE 50 
Suggestion RT (Std) Purity Suggestion 
RT 
(Std) Purity Suggestion 
RT 
(Std) Purity 
10 5.94 Sildenafil 6.00 100.00 Sildenafil 6.00 94.60 Sildenafil 6.00 84.50 Sildenafil Same finding as HSA. 
11 Nil                   Nil 
Sample not 
adulterated. 









With the increasing trend in adulteration of sexual enhancement health supplements with 
novel PDE-5 inhibitors and their analogues, screening for adulterants in sexual 
enhancement health products should not be restrictive to the 3 approved PDE-5 inhibitors 
(sildenafil, tadaladil and vardenafil). The developed LC-Hybrid Tandem MS method is 
useful for the rapid and simultaneous screening of a total of 25 PDE-5 inhibitors and 
related analogues in herbal supplements. The screening capacity of the system can be 










Isolation and structural elucidation of Flibanserin as an 





Sexual dysfunction is more prevalent for women (43%) than men (31%) and is associated 
with various demographic characteristics, including age and educational attainment 
(Laumann et al. 1999). Hypoactive sexual desire disorder (HSDD) is a form of Female 
Sexual Dysfunction (FSD). HSDD is defined as a persistent or recurrent deficiency (or 
absence) of sexual fantasies/thoughts and desire for sexual activity causing marked distress 
or interpersonal difficulty (American Psychiatric Association 2000). Up to 10% of women 
in the USA suffer from FSD of which HSDD is the major subindication (Shifren et al. 
2008). Sexual Desire Disorders are generally under-diagnosed as many women are 
reluctant to discuss sexual issues with their physicians and have low expectations 
concerning the prospects for help (Marwick 1999, Shifren et al. 2008). Currently, no 
pharmacological therapy is approved by US FDA for the treatment of HSDD. Some 
hormonal therapies have been used off-label mainly in postmenopausal women. With 
accumulating evidence indicating that low-dose testosterone treatment is efficacious in 
women with HSDD, more research into testosterone treatments designed specifically for 






2009, Simon 2005b, Simon et al. 2005a). A wide range of testosterone formulations, 
including injections, implants, transdermal patches, cream, gel and tablets have been 
studied, with varying results (Simon 2005b). Some of these therapies are in their late-stage 
clinical trials. 
 
Other than hormonal therapies, a wide range of pharmacologic agents have been evaluated 
for their efficacy in the treatment of HSDD. Some of these drugs have shown little 
potential for clinical use, whereas others have exhibited promise. Numerous investigations 
have examined whether vasoactive drugs used to treat erectile dysfunction in men might 
also improve sexual function in women (Berman et al. 2003, Segraves 2008). In general, 
no promising results are obtained from the studies of such agents (including 
phosphodiesterase inhibitors and alprostadil). Research focusing on dopaminergic drugs 
(such as levodopa, pergolide, and apomorphine) has yielded mixed results in women with 
HSDD (Segraves 2008, Segraves et al. 2001).  
 
With no approved HSDD therapies available to women, women with reservations to seek 
help from their physicians may turn to natural health products for help. As a result, health 
supplements for treating FSD have become increasingly popular in recent years as they are 
believed to be natural with no side effects. Many of these products claim to be libido 
enhancer that stimulates blood flow, circulation and hormone activity which result in a 










The objective of this study is to detect, isolate and identify an unknown compound in a 
health product claimed for sexual performance enhancement using LC-DAD, LC-FTMS, 







A health supplement, named MMP, was sent to the Health Sciences Authority (HSA) of 
Singapore for testing. It is presented as transparent capsules with white powder. Methanol 
(AR grade) and acetonitrile (HPLC grade) were supplied by Lab-Scan Analytical Sciences 
(Patumwan, Bangkok, Thailand). Methanol (HPLC grade) was supplied by RCI Labscan 
Limited (Thailand). Dimethylsulfoxide (DMSO) was supplied by Sigma-Aldrich 
(Steinheim, Germany). 0.45 µm nylon membrane filters were supplied by Whatman 
International Ltd. (Maidstone, UK). Ultrapure water was obtained using a Elga Purelab 
Water Purification System. Sodium dihydrogen phosphate was supplied by Sigma-Aldrich 
(Steinheim, Germany). Deuterated formic acid and deuterated chloroform used for NMR 







5.3.2 Extraction of sample 
 
For LC-DAD, 1 g of the capsular contents (white powder) were ultrasonically extracted in 
10 ml methanol (AR grade) for 30 min. 1 ml extract was further diluted to 10 ml with 
methanol (AR grade) and filtered through the 0.45 µm PTFE membrane filter.  
 
For LC-LTQ Orbitrap XL FTMS, NMR and IR analyze, 3.3 g of the capsular contents 
were ultrasonically extracted with 40 ml methanol (AR grade) for 30 min. The extract was 
filtered and the solvent was evaporated off using a rotary evaporator. The residue was 
reconstituted in 1.5 ml DMSO and filtered through 0.45 µm PTFE membrane filter. The 
filtered sample was further purified using preparative HPLC and the purified compound of 
interest was analyzed by LC-LTQ Orbitrap XL FTMS, NMR and IR.  
 
5.3.3 Preparative HPLC 
 
A Shimadzu HPLC system with two preparative pumps (LC-8A, Kyoto, Japan) and an 
automatic fraction collector (FRC-10A, Kyoto, Japan) were used. An Agilent ZORBAX 
SB-C18 reversed phase semi-preparative column (250 × 9.4 mm i.d., 5 µm) was used for 
the sample separation. The mobile phases were water and acetonitrile (HPLC grade). The 
gradient elution profile was as follows: acetonitrile was increased from 20% to 90% in 15 
minutes and maintained for 3 minutes. The flow rate of mobile phase was 4 ml/min and 
injection volume was 50 µl. Column oven temperature was set at 40 0C. The UV and 






Fractions containing the target compound were collected by the automatic fraction 
collector based on UV detection (254 nm). The solvent was removed using a rotary 
evaporator and the residue was freeze dried using Christ Alpha 2-4 LD Plus Freeze Dryer 
(Osterode, Germany).  
 
5.3.4 LC-DAD analysis 
 
An Agilent 1100 series HPLC chromatograph with diode-array detector (Palo Alto, CA, 
USA) was employed. A BDS Hypersil C18 column (200 mm × 4.6 mm i.d., 5 µm) from 
Thermo Scientific (USA) was used. Mobile phase A consisted of 25 mM sodium 
dihydrogen phosphate in water, adjusted to pH 3.2 ± 0.1 with phosphoric acid.  Mobile 
phase B was acetonitrile (HPLC grade). The gradient elution profile was as follows: 0–30 
minutes, acetonitrile rose from 10% to 70% (v/v), and maintained for 5 minutes. The flow 
rate of mobile phase was 1 ml/min. The injection volume was 10 µL. The UV spectra from 
200 to 400 nm were recorded on-line during the chromatographic run. The chromatograms 
of both original methanol extract and purified compound were recorded at the wavelength 
254 nm. 
 
5.3.5 LTQ Orbitrap XL FTMS analysis 
 
The isolated compound was dissolved in methanol (HPLC grade) at a concentration of 0.5 
µg/ml and was injected into Thermo Fischer Scientific LTQ Orbitrap XL™ hybrid FTMS 






ionization source was operated in the positive ionization mode with spray voltage set at 3 
kV, sheath gas flow rate at 40 arb, auxiliary gas flow rate at 10 arb, capillary voltage and 
temperature at 39 V and 250 0C respectively. The tube lens were set at 120 V, mass range 
was set at 200 to 500 Da at a resolution of 30000. The high-resolution MS spectrum was 
acquired by direct infusion with a flow rate of 5 µl/min. The [M+H]+ was selected as a 
precursor ion and the MS2 spectrum was acquired with Collision energy (CE) set at 45V 
under HCD (High energy Collision Dissolution) mode.  
 
5.3.6 NMR and IR analyses  
 
The isolated compound was dissolved in deuterated chloroform (CDCl3) for NMR analysis. 
13C and DEPT spectra were recorded on a Bruker AMX 500 spectrometer (Bruker BioSpin, 
Rheinstetten, Germany). 1H, COSY, HMQC and HMBC spectra were recorded on a 
Bruker DRX 500 spectrometer (Bruker BioSpin, Rheinstetten, Germany). Chemical shifts 
were reported in ppm using the solvent peak as an internal standard. IR spectrum in KBr 
disc was recorded on a Nicolet 6700 FTIR spectrometer (Madison, Wisconsin, United 
States) and recorded over the spectral range 4000–400 cm-1. 
 
5.4 Results and Discussion 
 








As shown in Figure 5.1, the UV spectrum of the isolated unknown compound in methanol 
showed maximal absorbances at 210 nm, 230 nm, 250 nm and 280 nm. The retention times 
for the compound in both the extract and purified sample were 17.2 min and 17.4 min 
respectively under the LC-DAD chromatographic conditions [Figure. 5.2 (A) and (B)].  
 




Figure 5.1  UV-vis spectrum of unknown compound in methanol, scanned 
from 200 nm to 400 nm, showing the maximal absorbances at 210 nm, 















Figure 5.2  HPLC chromatograms of (A) methanol extract of MMP and (B) 






High-resolution ESI-MS spectrum (Figure 5.3) of the compound revealed [M+H]+ 
at m/z 391.17310, suggesting a molecular formula of C20H21F3N4O. The error 
between observed mass and theoretical mass of [M+H]+ was -2.352 ppm. 
 
The high-resolution MS2 spectrum by high-resolution ESI-MS/MS in Figure 5.4 
showed the major fragments at m/z 161.07045, 204.11269, 243.10999, 257.12555 
and 371.16727. The proposed chemical structure of the unknown is shown in 
Figure 5.5.  




Based on the proposed chemical structure, the fragmentation process proposed by 
Mass Frontier™ 5.0 (HighChem, Ltd., Slovak Republic) is shown in Figure 5.6.. 
All proposed fragments have mass errors below 5 ppm. 






















                 
 
              
 
 
          
             
                
m/z 204.11269 
(mass error : -2.205 ppm) 
m/z 161.07045 
(mass error : -3.042 ppm) 
m/z 119.05988 
(mass error :  -4.116 ppm) 
m/z 371.16727 
(mass error : -1.401 ppm) 
m/z 257.12555 
(mass error : -1.789 ppm) 
m/z 391.17310
(mass error : -2.352 ppm) 
m/z 391.17310 
(mass error : -2.352 ppm) 
m/z 391.17310 
(mass error : -2.352 ppm) 
m/z 391.17310 










This proposed formula and structure was further confirmed by 1H and 13C NMR 
data which indicated the presence of 20 carbon atoms and 21 protons. 1D and 2D 
NMR (Table 5.1) data were used to assign the protons and carbon atoms. In the 
1H NMR spectrum (Table 5.1), a sharp singlet at 10.00 ppm integrating for one 
proton is a typical proton attached to nitrogen. HMBC correlated this proton to C-
2, C-4, and C-9 suggesting that it was H-3. Complex signals were observed 
between 7.00 to 7.31 ppm, integrating for eight protons. A triplet at 7.31 ppm, 
integrating for a proton has a coupling constant of 8.0 Hz. HMBC correlated this 
proton with C-16, C-19, and C-21 suggesting that it was H-20. A double-doublet 
splitting pattern at chemical shift 7.11 ppm, integrating for a proton, has coupling 
constants of 6.3 Hz and 1.6 Hz. HMBC correlated this proton to C-6, C-7, and C-
9 showing that it was H-8. Overlapped signals were observed from 7.04 ppm to 
7.10 ppm, integrating for five protons. A double-doublet splitting pattern at 7.01 
ppm with coupling constant 8.0 Hz and 2.0 Hz, integrating for a proton was 
observed. HMBC correlated this proton to C-17 suggesting that it was either H-19 
or H-21. Four triplet signals were also observed from 2.73 ppm to 4.08 ppm, 
integrating for a total of twelve protons. Two of these triplet signals at 2.74 ppm 
and 3.22 ppm integrated for four protons each, suggesting overlapping signals of 
methylene protons. This was further confirmed by 13C and DEPT NMR. 
 
13C and DEPT NMR data showed the signals of four methylene, eight methine 
and six quaternary carbon atoms. The DEPT signals at 53.1 ppm and 48.6 ppm 






signals, suggesting two methylene carbon atoms each contributing to the signal at 
53.1 ppm and 48.6 ppm. HMQC results further indicated that these two methylene 
carbon signals at 53.1 ppm and 48.6 ppm were correlated to the protons signal at 
2.73 ppm and 4.08 ppm respectively, which corresponded to four protons each. 
The finding confirmed overlapping methylene carbon signals (at 53.1 ppm and 
48.6 ppm) and methylene proton signals (at 2.73 ppm and 4.08 ppm). Hence, the 
unknown compound has six methylene carbon atoms with a total of twelve 
methylene protons. The chemical shifts of the twelve methylene protons 
suggested that they were attached to relatively electronegative atoms. It was 
speculated that the six methylene groups were attached to the nitrogen atoms and 
the electron withdrawing effect of these electronegative nitrogen atoms resulted in 
the deshielding of the protons. HMBC and COSY correlations were used to assign 
the rest of the protons.  
 
The 13C NMR data (Table 5.1) showed that there were two quaternary carbon at 
155.6 ppm and 151.3 ppm. The carbon with chemical shift 155.6 ppm was C-2. In 
the structure of imidazolone, carbonyl carbon C-2 was attached to two nitrogen 
atoms which helped to withdraw electrons from oxygen to C-2. Hence, C-2 was 
less deshielded as compared to a normal carbonyl carbon which has chemical shift 
above 170 ppm. Eight methine carbons and two quaternary carbons with chemical 
shifts above 108 ppm suggested the presence of two aromatic rings. The 






three fluorine atoms. Due to the strong electron withdrawing effect of the fluorine 
atoms, C-22 was highly deshielded and had a high chemical shift.  
 
The 1H and 13C NMR , DEPT, HMQC, HMBC and  1H-1H COSY spectra are 
shown in Figure 5.7 to 5.12.    
 
The NMR results confirmed the unknown compound to be 1-[2-[4-(3-
trifluoromethyl phenyl) piperazin-1-yl] ethyl] benzimidazol-[1H]-2-one, which is 
also known as flibanserin. The chemical structure of flibanserin is the proposed 
structure in Figure 5.5.       
 
The IR spectrum of the isolated compound showed absorption bands of amide 
(νC=O 1685 cm-1, νN-H (stretch) 3180 cm-1, νN-H (bending) 1610 cm-1), alkyl fluoride (νC-F 
1077 cm-1, 1112 cm-1, 1158 cm-1), aromatic ring (νAr-H 3028 cm-1, 3078 cm-1 and 
νC=C 1401 cm-1, 1446 cm-1, 1453 cm-1, 1468 cm-1, 1487 cm-1) and alkane (νC-H 
2891 cm-1, 2930 cm-1 2948 cm-1). The IR spectrum supported the structure of 
flibanserin.     
 
Flibanserin, a serotonin-1A (5-HT (1A)) receptor agonist and the serotonin-2A (5-
HT (2A)) receptor antagonist was developed as a novel, non-hormonal treatment 
for pre-menopausal women with HSDD (Borsini et al. 2002, Invernizzi et al. 
2003). However, the FDA Advisory Committee for Reproductive Health Drugs 






robust to justify the risks and there were concerns over the safety signals and 
potential drug interactions involving flibanserin (US FDA 2010e). Data on long 








                     






                             





































          







Table 5.1  NMR data for unknown compound 
No. 1H (δH) 
13C 
(δC) DEPT** COSY HMBC 
2 ─ 155.6 0 ─ ─ 
3 10.00 (1H, s) ─ ─ ─ C-2, C-4, C-9 
4 ─ 128.1 0 ─ ─ 
5 7.06 (1H, m) 108.0 1 ─ C-4 
6* 7.10 (1H, m) 121.3 1 ─ *** 
7* 7.10 (1H, m) 121.6 1 ─ *** 
8 7.11 (1H, dd, J = 6.3, 1.6) 110.0 1 ─ C-6, C-7, C-9 
9 ─ 130.3 0 ─ ─ 
10 4.08 (2H, t, J = 6.8) 38.5 2 H-11 C-2, C-9, C-11 
11 2.80 (2H, t, J = 6.8) 55.7 2 H-10 C-10, C-12, C-14 
12, 14 2.74 (4H, t, J = 4.5) 53.1 2 H-13, H-15 C-11, C-13, C-15, C-
12/C-14,  
13, 15 3.22 (4H, brs) 48.6 2 H-12, H-14 C-12, C-14, C-13/C-
15, C-16 
16 ─ 151.3 0 ─ ─ 
17 7.09 (1H, m) 112.2 1 ─ *** 
18* ─ 123.2 0 ─ ─ 
19 7.01 (1H, dd, J = 8.0, 2.0) 115.8 1 H-20 C-17 
20 7.31 (1H, t, J = 8.0) 129.5 1 H-21/H-19 C-16, C-19, C-21 
21 7.07 (1H, m) 118.7 1 H-20 *** 
22* ─ 125.4 0 ─ ─ 
δppm in CDCl3, J in Hz. 
* Overlapping signals 
** Number of attached protons 













Figure 5.13  FTIR spectrum of unknown compound 
 
       C=C stretch (aromatic) 







5.5  Conclusion 
 
In this study, a serotonin-1A (5-HT (1A)) receptor agonist and serotonin-2A (5-
HT (2A)) receptor antagonist, flibanserin, was isolated from a health supplement 
and its chemical structure was elucidated using NMR, IR, high-resolution ESI-MS 
and MS/MS. The presence of flibanserin in the health supplement is dangerous 
for consumers as it is not an approved drug. This is the first report of flibanserin 
as an adulterant in a health supplement used for female sexual performance 
enhancement. Due to the limited amount of sample available, quantitative analysis 









There is a global upsurge in the use of herbal medicines in both developed and 
developing countries over the years. As the regulatory control for herbal 
medicines is less stringent than that for the conventional pharmaceuticals, the 
safety and quality of these products pose a concern to the consumers. The 
adulteration of herbal sexual enhancement health products with unlabeled 
synthetic therapeutic substances such as PDE-5 inhibitors and their related 
analogues is hazardous to public health and severe adverse effects may develop 
with the consumption of such adulterated products.  
 
The study on the safety and quality assessment of the 247 illegal sexual 
enhancement herbal products seized by HSA from the red light districts and at 
Singapore Customs revealed that a high proportion of these products (199, 77%) 
were adulterated with western drugs and their analogues. The extent of the 
adulteration may in part explain the effectiveness and the high demand for such 
products despite the many adverse drug reactions reported. As there are currently 
no registration requirements for herbal medicines except for a listing system for 
CPM products in Singapore, adulterated sexual enhancement herbal supplements 
can escape from the listing requirement and pre-marketing safety assessment, 
which include the screening for adulteration. The study reveals the pressing need 






and to curb the demand of such products through public education. The study also 
provides a good reference for public education, creating greater public awareness 
on the danger of consuming illegal health supplements and dispelling the myth 
that “natural” means “safe”. Consumers are often reluctant to reveal to physicians 
and health authorities the nature of the products they have taken, the source of 
supply and identities of the distributors or peddlers, due to the sensitivity of the 
matter. Physicians should be encouraged to discuss with their patients about the 
consumption of herbal medicines and supplements and be aware of potential 
adverse events associated with the consumption of herbal medicines. Both the 
physicians and consumers should keep a lookout for such adverse events and 
should be encouraged to make an adverse drug reaction report to alert the 
authorities and manufacturers. This will help to prevent under reporting of 
adverse events associated with herbal products.  
 
With the emerging threat from adulteration of sexual enhancement health 
products, it is important for regulatory laboratories to develop a rapid and 
sensitive method to simultaneously detect PDE-5 inhibitors and their related 
analogues. This will enable the authorities to effectively control the sexual 
enhancement health products in the market and investigate the adverse reaction 
reports associated with the consumption of such products. The LC-Hybrid 
Tandem MS Screening System developed in this study for rapid and simultaneous 
detection of the PDE-5 inhibitors and their analogues in sexual enhancement 






vardenafil) and their 22 related analogues in a single run of 20 min. The 
developed method will be adopted by HSA to complement its current screening 
methodologies for sexual enhancement health products.       
  
In recent years, health products for treating female sexual dysfunction have also 
become increasingly popular as there are no approved hypoactive sexual desire 
disorder (HSDD) therapies available to women. Instead of seeking help from their 
physicians, such patients may turn to natural health products for help. In this 
study, a serotonin-1A (5-HT (1A)) receptor agonist and the serotonin-2A (5-HT 
(2A)) receptor antagonist, flibanserin, was isolated from a health supplement 
claimed to enhance female sexual performance. Its chemical structure was 
elucidated using NMR, IR, high-resolution ESI-MS and MS/MS. The findings 
allow HSA to follow up the case with the supplier and stop the product from entry 
to the local market. This is also the first report of flibanserin as an adulterant in a 
sexual performance enhancement health supplement. 
 
Herbal medicine is a complex mixture of biological origin. Effective control of 
the quality and safety remains challenging and requires regulatory control, 
scientific methodologies and data, post-marketing quality surveillance, 
pharmacovigilance, availability of reliable information and education of all 
stakeholders (industry players, healthcare professionals and consumers). It is 
important for the health authorities to recognize the urgent need for imposing 
effective statutory regulations to ensure the quality, safety, efficacy and 






encourage and support research development in the quality, safety and efficacy of 
herbal medicines, which includes the development of testing methodologies for 
the quality and safety control of herbal health products. The work presented in 
this thesis is useful to health authorities, healthcare professionals and consumers 
to ensure a safe integration of good quality herbal medicine into conventional 
medical practice. 
 
For future work, toxicity studies and pharmacokinetic investigations of the PDE-5 
inhibitor analogues reported will be useful to confirm the health risks involved in 
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S/N Product name/ description Batch Number Manufacture Dosage Form Ingredients Adulterant Detected Content 
1 18 Spring 十八春 30 ml - 深圳康妮尔保健品有限公司 
Pink tube with 
transparent cream  - No common poison detected 




Sildenafil 114.69 mg/cap 




Sildenafil 205.80 mg/cap 
4 Ai Jia Ai 爱加爱 - 香港大力神生物医药技术中心 
Red and black 
capsule  
冬虫夏草，人参，鹿鞭，
海狗肾 Sildenafil 210.28 mg/cap 




- No common poison detected 





Sildenafil 29.76 mg/tab 
7 America Cowboy 美国牛仔 - 香港华建国际贸易有限公司 Green capsule - Sildenafil 133.94 mg/cap 
8 American Moxman 美国魔根  2500 mg - - 
Red and white 
capsule - 
Sildenafil 139.72 mg/cap 
Sibutramine 0.011 mg/cap 











S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 




Sildenafil 12.31 mg/tab 
Vardenafil 25.40 mg/tab 
Piperidenafil Not determined 
11 America Viagra - - Yellow tablet with "HF" engraver - 
Sildenafil 156.91 mg/tab 
Sibutramine < 0.003 mg/tab  
12 Bai Wei 百威 - - Black tablet - Sildenafil 66.93 mg/tab 
13 Bai Wei USA 百威 - - Black tablet with "HF" engraver - Sildenafil  129.64 mg/tab 
14 Black King 黑金刚  Q/LXB010-2005 西藏升陽保健品有限公司 White capsule  - Sildenafil 145.05 mg/cap 
15 Black King Kong 黑金刚 - - Yellowish orange capsule - Sildenafil 200.56 mg/cap 
16 Blue Fairy U.S.A 蓝精灵   Bolin Merker Health Products Co. Ltd 
Transparent and 
white bottle - No common poison detected 
17 Buda 强神粒 - 拉萨市力达保健品有限公司 Brown tablet Sildenafil Sildenafil 81.35 mg/tab 
18 Buda 金槍不倒 Q/HS02-2000 拉萨市力达保健品有限公司 Red tablet  - Sildenafil  92.33 mg/tab 
19 Buda 金槍不倒 Q/HS02-2000 拉萨市力达保健品有限公司 
Red tablet with 
"800mg" engraver - Sildenafil 84.15mg/tab 






S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
21 Cang Ying Fen 苍蝇粉 - 日本红丸珠式会社 Sachet containing white powder 淫性草， 红参，鹿茸等。 No common poison detected 
22 Cang Ying Shui 苍蝇水 - 中国深圳祥瑞生物工程有限公司 White tube - No common poison detected 
23 Cattle Capsules 牛宝胶囊 - 安徽三体医药保健品公司 






Sildenafil 36.13 mg/cap 
24 Cattle Capsule 牛寳膠囊 - 安徽三體醫藥保健品公司  
Blue and white 
capsule with "牛宝
CATTLE" imprint 
Pizzie, antlar, ginseng, 
Schisandra fruit, lycium 
fruit, Cuscuta barren wort, 
Arillus Longan, astragalus 
root. 
Sildenafil 36.42 mg/cap 
25 Caverta 100 mg 5024541 Ranbaxy 




dioxide, iron oxide red, 
lake of indigo carmine 
and lake of ponceau 4R 
Sildenafil 71.36 mg/tab 
26 Caverta 100 mg (Ranbaxy) 1661385 Ranbaxy Brown tablet with "100" engraver 
Sildenafil, titanium 
dioxide, iron oxide red, 
lake of indigo carmine 
and lake of ponceau 4R 
Sample A:Sildenafil 30.33 mg/tab 
Sample 
A:Chloramphenicol 0.44 mg/tab 
Sample B:Sildenafil 115.68 mg/tab 
27 Champ - Gentlemen Only - - Yellow and transparent capsule - Lignocaine 0.105 mg/cap 
28 China Vigers 中华伟哥 2500 mg - 中国人民财产保险股份有限公司 












S/N Product name/description Batch Number Manufacture Dosage Form Ingredients Adulterant Detected Content 
29 China Vigers 中華偉哥  - 中国人民财产保险股份有限公司 





Sildenafil 134.00 mg/cap 






Rich highly purified 
composite oceanic life 
extract with supreme 
permeability, Sky Fruit, 
active compound 
combines various 
elements in natural herbal 
extract. Rich in various 
amino acids. Proteins, 
cellulose, VA, VB, VB2, 
VC, and DHA.  
Sildenafil 154.94 mg/cap 
Acetil acid Not determined 
31 Chong Cao Bu Jing Wan 虫草生精丸  - 
上海双龙生物有限





Sildenafil 76.09 mg/pill 
32 Chong Cao Duo Bian Wan  虫草多鞭丸 Q/CFS-068-2006 
海南長青保健品有




Sildenafil 137.72 mg/pill 
33 Chong Cao Lu Bian Wan  虫草鹿鞭丸 9 g - 
香港金龙生物有限




Sildenafil 160.48 mg/pill 
34 Chun Qing Xue Sheng Mei  純情學生妹 - - 
Sachet containing 







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
35 Cialis 20 mg A051038 Eli Lilly and Company Limited 






Hypromellose, Iron oxide 
yellow C177492, Lactose, 
Magnesium stearate, 
Cellulose-microcrystalline, 




Sildenafil 12.69 mg/tab 
Tadalafil 19.59 mg/tab 
36 Cialis Tadalafil 80 mg - Eli Lilly and Company Limited 







sodium lauryl sulfate, 
magnesium stearate, 
hypromellse, triacetin, 
titanium dioxide (E171), 
iron oxide yellow (E172), 
talc 














S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
37 Cialis 20 mg (bottle) 66018 Eli Llilly Australia Pty Limited 







hypromellose, iron oxide 
yellow C177492, lactose, 
magnesium stearate, 
cellulose-microcry 
stalline, sodium lauryl 
sulfate, talc-purified, 
titanium dioxide, glycerol 
triacetate 
Sildenafil 90.29 mg/tab 
38 Da Di Yong Shi 大地勇士 - - Brown tablet wth "TL" engraver - Sildenafil 114.44 mg/tab 
39 Dancing Lady - - Transparent cream  - No common poison detected 
40 Darling Peculiar Hormone Cream 愛人 - 香港製药有限公司 Transparent cream  - No common posion detected 
41 De Guo Hei Jin Gang 德国黑金刚 - 西藏拉萨市力龙生物制品有限公司 
Black tablet with 
"C200" engraver 
虎鞭，海狗鞭，牛鞭，人
参，淫羊藿。 Sildenafil 107.93 mg/tab 
42 De Guo Jin Gang Pen 德国金刚喷 - 西藏梅龙保健品有限公司 
White and brown 
bottle - Lignocaine 59.0 mg/ml 
43 Delay Spray 日本 M88 - Doc Johnson Enterprises  
Black spray bottle 
containing 
transparent liquid  
Lignocaine based USP Lignocaine 99.94 mg/ml 
44 Doc Johnson Delay Spray  日本 M88 - 
Doc Johnson 
Enterprises Black bottle Lignocaine Base USP  Lignocaine 127.0 mg/ml 
45 Di Liu Dai Yi Pao Dao Tian Liang 第六代一炮到天亮 QXM06-2003 
贵州宏源医药保健
品公司 





Sildenafil 114.55 mg/cap 






S/N Product name/description Batch Number Manufacture Dosage Form Ingredients Adulterant Detected Content 
46 Ding Chuan Tian 顶穿天 - 台湾神龙生物保健品开发有限公司 





Sibutramine 0.029 mg/cap 
Sildenafil 160.01 mg/cap 
47 Dong Fang Bu Bai  东方不败强神粒 - 
拉萨市力达保健品
有限公司 
Brown tablet with 
"800mg" engraver - Sildenafil 76.24 mg/tab 
48 Dong Fang Bu Bai 東方不敗 Q/HS02-2000 拉萨市力达保健品有限公司 
Red tablet with 
"800mg" engraver - Sildenafil 86.68 mg/tab 
49 Eros Delay Spray For Men - Savoy Laboratories (International) Ltd 
Yellowish orange 
and black bottle - Lignocaine 25.33% 




Black spray bottle 
containing 
transparent liquid  
Lignocaine BP 10% w/v  Lignocaine 52.86 mg/ml 
51 Exceed Viagra and Cialis  宏圣生物 - - Green capsule   - Sildenafil 25.50 mg/cap 
52 F + F Super Enforcement capsule 力加力 - - 
Yellowish orange 
capsule - Sildenafil 127.08 mg/cap 
53 Ferity Lily 野百合  - 西藏金聖力保健品有限公司  
Transparent bottle 
with pink cap 
containing 
transparent liquid  
- No common posion detected 





- No common poison detected 
55 French Silver Fox 法国银狐  2800 mg - - 
Sachet containing 
white powder - No common poison detected 
56 Formula For Man 壮阳极品 - - Green capsule with "金聖利" imprint - 
Sildenafil 136.79 mg/cap 






S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 





Grey and yellow 
bottle containing 
transparent liquid  
Water, fructose, flaror, 
etc. No common poison detected 
58 Gong Ting Sheng Bao 宫廷圣宝  - 香港天龙生物 
Light and dark blue 
capsule with “天龙制




Sildenafil 81.48 mg/cap 
59 Hao Gong Fu 好功夫 - 香港力龙生物技术有限公司 
Yellow tablet with 
“力龙” engraver 蜂房, 淫阳藿等。 Sildenafil 116.93 mg/tab 
60 Hei Gua Fu Cui Qing Fen 黑寡妇催情粉 2000 mg - - Sachet 
日本 inverma 原粉， 
淫性草，红参，鹿茸等 No common poison detected 
61 Hei Ma Yi Wang 黑蚂蚁王 - 西藏拉萨市力龙生物技术有限公司 




参，淫羊藿等 Sildenafil 101.43 mg/cap 
62 Hong Zhi Zhu 红蜘蛛 - 中国深圳祥瑞生物工程有限公司 
White and pink 
bottle - No common poison detected 
63 Hua Hu Die 花蝴蝶  - 西藏拉萨情力保健食品有限公司 
Red and transparent 
bottle containing 
white powder 





- No common poison detected 






Sildenafil 167.43 mg/cap 







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
66 Huang Wei Lu Rong 皇威鹿茸 - 秦皇岛皇威制药厂 Red capsule 鹿茸 
Sildenafil 73.65 mg/cap 
Sibutramine < 0.003 mg/cap 
67 India Doc Johnson Delay Spray - Doc Johnson Enterprises Black bottle Lignocaine Base USP  Lignocaine 178.0 mg/ml 
68 India External Lotion 印度久战油 - 海南平安生物制剂有限公司 Blue bottle - No common poison detected 
69 Indian God Lotion 印度神油 - 海南平安生物制剂有限公司 
Pink bottle with 
transparent liquid - No common poison detected 





No common poison detected 




- No common poison detected 
72 Ji Pin Lang Yi Hao 极品狼 1号  Q/LZB-002-2000 黑龙江省佳木斯市高新制药总厂 
Blue tablet with “DL” 
engraver 
鹿鞭，牛鞭，人参，海
马，海蛇，海星等 Sildenafil 89.28 mg/tab 
73 Ji Pin Zhong Hua Wei Ge  极品中华伟哥 - 
西藏拉萨市力龙生
物制品公司 
Green capsule with 




Sildenafil 127.79 mg/cap 






Pill: Naproxen       0.02 mg/cap 
Pill: Lignocaine      0.44 mg/cap 







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
75 Jin Gang Shen Dan 金刚神丹 - - 
Green capsule with 
“力龙生物”  
imprint  
- Sildenafil 158.54 mg/cap 
76 Jin Mao Shi Wang 金毛狮王 - 青海格尔木天马保健品有限公司 





Sildenafil 110.91 mg/tab 
77 Jing Ba 劲霸 - 中国 香港华人生物工程有限公司 White capsule 
人参，鹿茸，海狗鞭， 
五味子等 Sildenafil 107.15 mg/cap 
78 Jiu Chong Tian 九重天 - 九重天生物科技有限公司 
Red and beige 
capsule - Sildenafil 117.80 mg/cap 
79 Jue Dui Gao Chao Cui Qing Shui 绝对高潮催情水 - - 
Transparent and red 
bottle containing 
transparent liquid 
- No common poison detected 
80 K Fen K粉 - 中国 香港百家乐医药国际集团 Sachet 
Brazil hackmatack,  
betelnut, millet pox 
powder, peru panax, 
ethanol etc. 
No common poison detected 




- Lignocaine 0.12% 





Sildenafil 110.03 mg/cap 
Sibutramine < 0.003 mg/cap 
83 Kang Xi Da Di 康熙大帝 - 青海金聖力保健品有限公司 












S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
84 Kang Xi Da Di 康熙大帝 - 青海金聖力保健品有限公司 
Green capsule with 




Sildenafil 126.21 mg/cap 
Tadalafil 169.87 mg/cap 




蜂房, 淫阳藿等。 Lignocaine 32.0 mg/ml 
86 King Oil 皇帝油 - - - - Lignocaine < 0.24 mg/ml 
87 Lang Shen Yi Hao 800mg  狼神 1号 - 
西藏拉萨康威保健
品有限公司 





Sildenafil 105.77 mg/tab 
88 Lang Shen Yi Hao [Jin Wei Ge]  狼神一號 【金威哥】 Q/1LS-049-2001 
西藏拉萨康威保健
品有限公司 





Sildenafil 84.52 mg/tab 
89 Lang Wang 狼王 - 香港仁和堂生物研发有限公司 
Blue tablet with "DL" 
engraver 
鹿鞭， 藏牦牛睾丸， 
海马, 生精果，西洋参等。 Sildenafil 77.10 mg/cap 
90 Lang Yi Hao 极品狼 1号 145 mg - 黑龙江省佳木斯市高新制药总厂 
Blue tablet with "DL" 
engraver 
鹿鞭， 牛鞭，人参， 
海马，海蛇，海星等。 Sildenafil 107.57 mg/tab 
91 Lemak Lintah Leech Fat - - Transparent bottle with green liquid 
Essence of leeches, leech 
fats, eeches oil, hirudo 
medicinalis, cocos 
nucifera oil, aleurites 
maluccana .  








S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 




Leech fat, anguila 
mauritiana, essence of 
leech, nigella sativa, 
kaempferia galanga, cocs 
nucifera oil   
No common posion detected 
93 Levitra 20 0026K69 - Orange tablet with "100" engraver - 
Sildenafil 135.96 mg/tab 
Tadalafil 0.30 mg/tab 
94 Levitra 20 BXBLJJ1 - orange tablet with 20 marking   Sildenafil 61.82 mg/tablet 
95 Li Jia Li 力加力 - - Green capsule - Sildenafil 95.48 mg/cap 
96 Li Jia Li Chao Qiang Sheng Li Jiao Nang 力加力超强生力胶囊 - - 
Yellowish orange 
capsule - Sildenafil 123.59 mg/cap 
97 Li Wei Ruan Jiao Nang  立威软胶囊 - - Brown pill - Sildenafil 118.31 mg/pill 
98 Longer Vaigra 长效伟哥 - 深圳博尔康生物科技有限公司 




Sildenafil 129.86 mg/cap 
Sibutramine 0.061 mg/cap 




Lignocaine based USP Lignocaine 83.17 mg/ml 




Lignocaine based USP No common poison detected 
101 Love You Power 老虎油 - 郑州市金阳保健品有限公司 












S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
102 Love You 全新 2代老虎油 - 郑州市金阳保健品有限公司 





五味子，细辛等 No common poison detected 
103 Lu Quan 鹿泉 - - Red and yellow capsule - Sildenafil 43.65 mg/cap 
104 Magic Power Antiseptic Wet Tissue - - 
Sachet containing 
wet tissue 
Purified water, ethyl 
alcohol, fragrance, other 
active ingredients  
Lignocaine 86.06 mg/piece 




- No common poison detected 
106 Magic Power Tissue  - USA Standard New York 
Sachet containing 
wet tissue - Lignocaine 51.45 mg/piece 
107 Mei Guo Lan Jing Ling  美国蓝精灵 (bottle) - 
香港艾得生物技术
有限公司 Green capsule Lignocaine (USP) 9.6% 
Sildenafil 79.37 mg/cap 
Sibutramine 0.015 mg/cap 
108 Mei Guo Mo Bang 美国魔棒  2500 mg - 
香港力龙生物技术




Sildenafil 90.44 mg/cap 
109 Mei Guo Zhan Shen 美国战神 - 香港科龙科技有限公司 Brown tablet - 
Sildenafil 3.64 mg/tab 
Vardenafil 21.19 mg/tab 
110 Mei Guo Mo Bang 美国魔棒 z/LZB003-2004 西藏拉萨市力龙生物技术有限公司 






Sildenafil 130.23 mg/cap 
111 Mei Guo Zhan Shen 美国战神 - 西藏美龙保健品有限公司 
White, transparent 






S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
112 Mei Guo Zhan Shen 美国战神 - 西藏拉萨市力龙生物技术有限公司 





Sildenafil 77.65 mg/cap 
Tadalafil 0.055 mg/cap 
113 Mei Guo Zhan Shen 美国战神 50212 香港太和堂生物工程有限公司 





Sildenafil 146.05 mg/tab  
114 Mei Guo Zhan Shen 美国战神 Z/LZB003-2004 香港力能生物技术有限公司 





Sildenafil 78.49 mg/cap 
Tadalafil 0.31 mg/cap 
115 Meng Hu Bei Zeng 猛虎倍增 - - Red capsule - Sildenafil 70.14 mg/cap 




Natural herbal extract Lignocaine <0.24 mg/ml 
117 Migino - - Transparent and green capsule - Lignocaine 5.14 mg/cap 
118 Minyak Lintah Tapa Plus 60 ml (bottle) - 





- No common poison detected 







Hiruda medicinal, leech 
oil, essence of leech, 
cocos nuchifera.  
No common poison detected 




Hiruda medicinal rhizoma 
smilax, essence of leech, 
cocos nucifera  
No common poison detected 







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
122 Mo General 猛男魔根   - 西藏拉萨市多得生物制品公司 
Yellow tablet with 





Sildenafil 136.88 mg/tab 
123 Nan Gen Jing Hua Su 男根精华素 - 香港金黄金科技开发有限公司 





Sildenafil 104.96 mg/cap 
Sulfosildenafil - 
Sulfohomosildenafil - 
124 Nan Shi Zhuan Yong 男士专用 - - Green capsule  - Sildenafil 191.43 mg/cap 
125 Niu Bian Da Bu Wan 牛鞭大补丸 Q/JDS060-2007 延吉康力保健品有限公司 
Opaque ball 
containing black pill 
虫草，牛鞭，黄精，锁
阳，龟板，当归，海马等 
Sildenafil 135.94 mg/pill 
Tadalafil 161.42 mg/pill 
126 Old Captain Sex Drops  - 薹灣梁氏醫藥集團 
Transparent bottle 
containing 
transparent liquid  
L- arginine, aloe vera.  No common posion detected 
127 Ottofol  - - 
Transparent tube 
containing dark blue 
cream 
- No common poison detected 




white powder - No common poison detected 







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
130 Pfizer Viagra 100 mg 314833021 Pfizer Inc 
Blue tablet with 
“Pfizer” engraver on 
one side and “VGR 
100” engraver on 
the other 
- 
Sildenafil 65.40 mg/tab 
Tadalafil 1.04 mg/tab 
131 Pfizer Viagra 100 mg (bottle) 04R006A Pfizer Inc 
Blue tablet with 
“Pfizer” engraver on 
one side and “VGR 












Sildenafil 62.23 mg/tab 
Tadalafil 0.07 mg/tab 
132 Playboy Cream - 
Union & Son 
Limited PO. Box 
432 
Orange and white 
tube containing 
transparent cream  
- No common  oison detected 
133 Posh for Men Only - - Transparent and yellow capsule - Lignocaine 18.58 mg/cap 




- No common poison detected 
135 Power 1 Walnut 动力一号核桃素片 20080106 广州新快力企业有限公司 
Pink tablet with 
“PIS-100” engraver - 
Glibenclamide 98.85 mg/tab 
Sildenafil 1.56 mg/tab 
136 Power 1 Walnut 动力一号核桃素片 20070918 广州新快力企业有限公司 
Pink tablet with 
“PIS-100” engraver - Sildenafil 68.45 mg/tab 







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
138 PT. Timur SujinTong Wan 舒经通  - Pi Timur Red and yellow capsule - No common poison detected 
139 Qiang Gen Bao Jiao Nang  强根宝胶囊 - - Green capsule - Sildenafil 76.43 mg/cap 
140 Qiang Jin Shen Qi Yi Li OK  强劲神奇 一粒 OK 
- 
- 
Blue tablet with 
“VAG” engraver - Sildenafil 46.50 mg/tab 
- Blue tablet with “800mg” engraver  - Sildenafil 48.46 mg/tab 
141 Qiang Jin Wei Ge Wang 500 mg  强劲威哥王 - - 





Sildenafil 34.23 mg/tab 
142 Qiang Jin Wei Ge Wang 800 mg  强劲威哥王 - - 
Blue tablet with 
“800mg” engraver  
海狗鞭，水牛鞭，广狗
鞭，羊鞭，鹿鞭，人参，
枸杞子。   
Sildenafil 15.66 mg/tab 
Tadalafil 0.020 mg/tab 
143 Qiang Jin Wei Ge Wang 1000 mg  强劲威哥王 - - 





Sildenafil 29.07 mg/tab 
Tadalafil 0.016 mg/tab 
144 Qiang Jin Wei Ge Wang (Chao Nong Suo) 强劲威哥王(超浓缩) 200 mg - - 
Blue tablet with 
“200mg” engraver  - Sildenafil 39.73 mg/tab 
145 Qiang Li Wei Ge Wang 强力威哥王   - - Blue tablet with “800mg” engraver - 
Sildenafil 33.34 mg/tab  







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
146 Qiang Shen Xiao Jin Wan 3 g  强肾小金丸 - 
西藏升阳保健品有




Sildenafil 105.39 mg/pill 
147 Raging Fire Girl 100311 Doc Johnson Enterprises 
Transparent bottle 
containing 
transparent liquid  
L-arginine, aloe vera No common poison detected 
148 Real Man - - 
Yellowish orange 
tablet with “DL” 
engraver 
- Sildenafil 121.65 mg/tab 
149 Reman’s Delay Spray D00Z
® 
14000 SPRAY - Reman Enterprises 
Blue spray bottle 
containing 
transparent liquid  
- Lignocaine 87.13 mg/ml 
150 Rogen Cream  - Sankyo Zoki Co. Ltd 
Black and yellow 
tube containing 
transparent cream  
- No common  oison detected 




- No common  oison detected 




- No common poison detected 
153 San Ti Niu Bian 三體牛鞭 Q/WS-9-95 安徽三体医药保健品公司 







Sildenafil;  28.02 mg/cap 
154 San Ti Niu Bian Bo Dong Li  三體牛鞭勃动力 Q/WS9-95 
安徽三体医药保健
品公司 















S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
155 Santi Scalper Penis Erection capsules 三体牛鞭 - 
安徽三体医药保健
品公司 







Sildenafil 28.66 mg/cap 
156 Sex Fairy 性精灵 - - Sachet containing white powder - No common poison detected 
157 Shen Bai Jin 肾白金 - 西藏拉萨市力龙生物制品公司 
Blue and white 
capsule with "力龙生
物" imprint 
- Sildenafil 189.23 mg/cap 
158 Shen Bai Jin Sheng Li Jiao Nang Di San Dai 腎白金生力膠囊第三代 HO5023 
西藏拉萨市力龙生
物制品公司 




参，淫羊藿等 Sidenafil 137.72 mg/cap 





Sildenafil 90.59 mg/cap 
160 Sheng Jing Jiao Nang 生精胶囊 - 香港天龙生物  
Green and light 
green capsule with "
天龙制造" imprint 
- 
Sildenafil 130.91 mg/cap 
Tadalafil 0.19 mg/cap 
161 Sheng Jing Pian 生精片 - 香港天龙生物科技（国际）集团公司 
Black tablet with 
"TL" engraver - Sildenafil  123.68 mg/tab 




- Sildenafil 121.34 mg/cap 
163 Sex Power Happy Factor - 
HongKong Jin 
Sheng Li Health 











S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
164 Shi Bian Wan十鞭王 1000 mg - 西藏金圣力保健品有限公司 






Sildenafil 21.19 mg/tab 
165 Shi Wei Hei Bing Pian Wan 十味黑冰片丸 - 西藏聂拉木藏药厂 Black pill - No common poison detected 




- No common poison detected 




- No common poison detected 
168 Stud 100 - Stud Holdings Limited 




Lignocaine (USP) 9.6% Lignocaine 252.0 mg/ml 
169 Super Cialis超级西力士 - - Yellow tablet - Sildenafil 18.18 mg/tab 
170 Super is Fierce Male 超级猛男 - 香港天雄医药生物技术有限公司 
White capsule with "
天雄制造" imprint 
Ginseng, Lilac glucoside,
Garlic, Lily, Chinese 
Angelica, Fruit of the 
Chinese wolfberry, aweto, 
epimedium leaf, merinda 
officinalis. 
Sildenafil 141.40 mg/cap 
171 Super Penis 超级男根 1800 mg - 西藏升阳保健品有限公司 
Yellowish orange 
capsule - Sildenafil 145.09 mg/cap 




Brown tablet with 







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
173 Super Power Pills 力加力 - 西藏拉萨康威保健品有限公司 





Sildenafil 151.97 mg/tab  




Lignocaine (USP) 8.2% Lignocaine 0.83 mg/g 
175 Supra Ginseng  - Royale Pharmacy New York U.S.A Orange tablet  
American Ginseng, 
Vitamin A, D, B1, B2, B6, 
B12, C, E. Nicotinamide. 
Choline bitartrate, biotin, 
lysine, methioinine, 
lecithin, linoleic acid.  
No common poison detected 
176 Te Zhi Wu Ye Shen 特制五夜神 - 香港天龙生物科技（国际）集团公司 





Sildenafil 107.73 mg/tab 
177 Tian Di Ying Xiong 天地英雄  2000 mg - 
西藏拉萨神威生物
工程有限公司 Pink tablet   
Tibetan goat penis, 
Tibetan ox penis, Tibetan 
horse penis, deer penis, 
sea dog penis, Tibetan 
donkey penis, actinolite, 
cynomorium.  
Sildenafil 149.88 mg/tab 
178 Tian Di Ying Xiong 天地英雄  - 天龙生物 Orange and white capsule - Sildenafil 112.70 mg/cap 
179 Tian Long 天龙 - 天龙生物 Orange and white capsule - Sildenafil 109.87 mg/cap 
180 Tian Xiong天雄霸王片 - - White capsule with “天雄制造” imprint - 
Sildenafil 56.466 mg/cap 







S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
181 Tian Xiong 天雄保健 - - White capsule - 
Sildenafil 127.90 mg/cap 
Tadalafil 6.19 mg/cap 
182 Tian Xiong Wei Meng Nan Ren 天雄威猛男人 - 
香港天雄医药生物技
术有限公司 
White capsule with 
“天雄制造” imprint  - Sildenafil 126.98 mg/cap 
183 Tiang Xiong Zhuang Yang Wang 天雄壮阳王 3000 mg - 
香港天雄医药生物技
术有限公司 
White capsule with 
“天雄制造” imprint  
鹿鞭,  牦牛睾丸, 黄精，锁
阳，龟板，当归，海马等 
Sildenafil 149.69 mg/cap 
Tadalafil < 0.003 mg/cap 
184 Tongkat Ajimat Madura 快活棒 - Persatuan Jamu Madura Asli  White herbal stick  - No common  oison detected 
185 Tongkat Ali Ginseng Habbatus Sauda - RFL Jamu Corner 
Transparent capsule 
with brownish green 
powder  
Eurycoma longifolia 40%, 
radix ginseng 30%, 
nigella sativa 30% 
No common poison detected 
186 Tongkat Ali Ginseng Ubi-Jaga - Perusahaan Jamu Salina 
Transparent capsule 
with brownish green 
powder 
Eurycoma longifolia 40%, 
radix ginseng 30%, 
nigella sativa 30% 
No common poison detected 




- No common poison detected 




- No common poison detected 
189 Tuo Yi Nv Lang 脱衣女郎 - - Sachet containing white powder - No common poison detected 














S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
191 V6 Tian  - 
HONGKONG TIAN 
XIONG YI YAO 
SHENG WU KE JI 
YOU XIAN GONG SI 
Green tablet with 
“TX” engraver - Sildenafil 134.12 mg/tab  
192 Viagra  04R006A Pfizer Laboratories 
Blue tablet with 
“Pfizer” and “VGR 
100” engraver 
- 
Sildenafil 125.65 mg/tab 
Tadalafil 1.80 mg/tab 
193 Viagra Doc Johnson Delay Spray 伟哥神油  - 
美国 Doc Johnson  
公司  
Black spray bottle 
containing 
transparent liquid  
- Lignocaine 87.77 mg/ml 
194 Vimax 增大丸 700 mg - - Blue and white capsule 海狗性腺提取物 Sildenafil 127.89 mg/cap 




- No common poison detected 
196 Wake 金刚一号 - - Yellowish orange bottle - Lignocaine 17.000 mg/ml 
197 Wei Ba Wang 800 mg 威霸王 - 海口宏大医药保健品公司 
Blue tablet with 
“800mg” engraver 
黄牛鞭，海狗鞭， 
人参 ，海龙，肉苁蓉。 Sildenafil 40.898 mg/tab 
198 Wei Ge 99 偉哥 99  Q/LZB-003-2003 西藏拉萨市力龙生物制品公司 




参，淫羊藿等 Sildenafil 133.13 mg/cap 
199 Wei Ge Xing Ba Wang - - Green capsule with “力龙生物” imprint  - Sildenafil 88.39 mg/cap 
200 Wei Meng 威の猛 - 天津市纪元保健用品厂 
Silver and black 
bottle - Lignocaine 38.0 mg/ml 












S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
202 Wu Di Wei Ge 无敌伟哥 60708 - 
Blue and white 
capsule with “力龙生
物” imprint 
- Sildenafil 123.14 mg/cap 
203 Wu Ye Shen 五夜神 - 香港天龙生物科技（国际）集团公司 
Yellow tablet with 
“TL” engraver 
鹿鞭， 牦牛睾丸，黄精，
锁阳， 龟板， 当归， 海
马等。 
Sildenafil 123.25 mg/tab 
204 Wu Ye Shen  五夜神 - 青海格尔木市雪峰生物工程有限公司  
Light green and 
dark green capsule  
西洋参，田七，雄蛾，牛
鞭，狗鞭，蜻蜓, 狗脊，植
物花粉等   
Sildenafil 105.61 mg/cap 
205 Xi Men Qing 西門慶 Q/LZS-026-2001 西藏拉萨力达保健食品有限公司 
Red tablet with “LD” 
engraver  鹿鞭，狗鞭，海狗鞭等 Sildenafil 85.22 mg/tab 
206 Xi Yu Shen Bao 西域肾宝 - - - - Sildenafil 107.37 mg/tab 
207 Xi Zang La Sa 西藏拉萨 500 mg - 西藏拉萨藏大保健食品公司 
Blue tablet with 
“500mg” engraver - Sildenafil 97.29 mg/tab 
208 Xin Yi Dai Hei Ma Yi Wang  新一代黑螞蟻王  - 
西藏拉萨市力龙生
物制品公司 
Red and white 
capsule with “力龙生
物” imprint  
虎鞭，海狗鞭，牛鞭， 人
参，淫羊藿等 Sildenafil 200.02 mg/cap 
209 Xin Yi Dai San Ti Niu Bian  新一代三体牛鞭 - - 
Blue and white 
capsule with “勃动
力” imprint 
- Sildenafil 23.04 mg/cap 
210 Xing Ba Wang 性霸王 - - Green capsule - Sildenafil 110.50 mg/cap 








- No common poison detected 






S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
213 Ye Tai Yang Jiao Nang  野太阳胶囊 - 
西藏九重天生物科
技有限公司 





Sildenafil 41.45 mg/cap 
214 Ye Ye Bu Dao 夜夜不倒 - - Yellow tablet with “C100” engraver - Sildenafil 102.71 mg/tab 
215 Ye Lai Xiang 夜来香 - 深圳康妮尔保健品有限公司 
Blue tube containing 
transparent cream - Lignocaine < 0.24 mg/ml 
216 Ye Tai Yang Jiao Nang  野太陽胶囊 - 
西藏九重天生物科
技有限公司  





Sildenafil 139.66 mg/cap 
Sibutramine 0.44 mg/cap  
217 Yeilus 一粒神 - 香港天龙生物科技(国际)集团公司 





Tadalafil 12.97 mg/cap 
Sildenafil 91.72 mg/cap 





囊” imprint  
- Sildenafil 119.49 mg/cap 
- Yellow capsule - Sildenafil 126.20 mg/cap 






Sildenafil 117.02 mg/tab 
220 Yi Li Wang 蚁力王 - 西藏拉萨神威生物工程有限公司 











S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
221 Yi Li Ting 一粒挺 Q/JH01-2004 青海西宁宏达保健品有限公司 
Blue and white 
capsule  
牦牛鞭，鹿鞭，海马，锁
阳等 Sildenafil 110.42 mg/cap 
222 Yi Pao Dao Tian Liang一炮到天亮 20070505 贵州宏源医药研究中心 





归， 海马等。  
Sildenafil 105.43 mg/cap 
223 Yin De Kuai 硬得快 - 西藏拉萨市神力保健品有限公司 





Sildenafil 14.84 mg/cap 
224 Yin Du Shen You 印度神油 - 海南平安生物制剂有限公司 Brown solution - No common poison detected 
225 Ying Da Wang 硬大王 - 西藏升阳保健品有限公司 





Sildenafil 131.41 mg/tab 
226 Ying Xiong Sheng Li Pian  英雄生力片 Q/HS 02-2004 
拉萨市力达保健品
有限公司 Blue tablet - Sildenafil 94.75 mg/tab 






Sildenafil 151.84 mg/cap 














S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
229 Zang Wang Xiong Ying 藏王雄鹰 - 中国 西藏宇拓健康品有限公司 Blue capsule 
Cordyceps 5%, Radix 
Ginseng 15%, Rhizoma 
Rhodiola 45%, Stigma 
Croc 15%, Rhizoa 
Gymnadenia 20% 
Sildenafil 86.94 mg/cap 
230 Zang Wang Xiong Ying - - Blue capsule - Sildenafil 93.31 mg/cap 
231 Zeng Chu Zeng Da  增粗增大 延时片 - 
西藏拉萨市藏大保
健品有限公司 
Blue tablet with 
"500mg" engraver - Sildenafil 98.87 mg/tab 
232 Zeng Cu Zeng Da  增粗增大 Q/320583XOS001-2000 
西藏拉萨市藏大保
健品有限公司 
Blue tablet with 
"500mg" engraver 
马苁蓉，肉苁蓉，人参，
鹿茸，牛鞭，羊鞭 等 Sildenafil 89.86 mg/tab 




transparent liquid  
- No common posion detected 
234 Zhuang Gen Jing Hua Su  壮根精华素 - 
香港天龙生物科技
（国际）集团公司 
Red capsule with "




Tadalafil 14.95 mg/cap 
Sildenafil 112.08 mg/cap 
235 Zhuang Gen Jing Hua Su  壮根精华素 20070302 
香港天龙生物科技
（国际）集团公司 
Red capsule with "
天龙制造" imprint 
鹿鞭， 牦牛睾丸，黄精，
锁阳， 龟板， 当归， 海
马等。  
Sildenafil 107.38 mg/cap 
236 Zhuang Gen Jing Hua Su 壮根精华素  - 
香港天龙生物科技
（国际）集团公司 













S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
237 Zhuang Gen Ying Da Wang 壮根硬大王 - 
西藏升阳保健品有限
公司 





Sildenafil 117.45 mg/tab 
238 Zhong Han Sheng Wu  中韓生物 - - 
Red tablet with 
“SUPER” engraver - Sildenafil 140.54 mg/tab 
239 Zhong Hua Niu Bao 中华牛宝 1800 mg - 
西藏金盛利保健品有
限公司 Black tablet 
牛鞭，牛肾，人参， 
淫羊藿，红花，枸杞等。 
Sildenafil 115.55 mg/tab 
Tadalafil 0.018 mg/tab 
240 Zhong Hua Niu Bian中华牛鞭 - 中国深圳市康力生物科技开发有限公司 
Orange and grey 
capsule 
Collagen, active peptide, 
mucase, vitamins, 
multiple acid And over ten 
micro elements such as 
calcium, iron, phosphor, 
strontium, manganese, 
copper.  
Tadalafil 0.072 mg/cap 
Sildenafil 87.11 mg/cap 
241 Zhong Hua Niu Bian 中华牛鞭 - 青海省康力生物科技开发有限公司 






Sildenafil 117.31 mg/cap 
Tadalafil 0.09 mg/cap 
242 Zhong Hua Niu Bian 中华牛鞭 800 mg - 
西藏升阳保健品有限
公司 
Yellow tablet with 




Sildenafil 92.73 mg/tab 
243 Zhong Hua Niu Bian 中华牛鞭 1500 mg - 
青海省康力生物科技
开发有限公司 













S/N Product name/description Batch Number Manufacturer Dosage Form Ingredients Adulterant Detected Content 
244 Zhong Hua Niu Bian 中华牛鞭 - 青海省康力生物科技开发有限公司 
Grey and orange 
capsule - 
Glibenclamide 13.06 mg/cap 
Sildenafil 93.38 mg/cap 
245 Zhong Hua Niu Bian 中华牛鞭  - 青海省康力生物科技开发有限公司 






Sildenafil 102.84 mg/cap 
Tadalafil 0.87 mg/cap 
Sibutramine 0.25 mg/cap 
246 Zhuang Yang Dan 壮陽丹 - - Brown pill 淫羊藿，金樱子，菟丝子， 虎鞭等 Vardenafil 0.10 mg/pill 
247 Zhuang Yang Dan 壮陽丹 K/PB/08-2002 - Brown pill 淫羊藿, 金樱子，菟丝子，虎鞭 等 Sildenafil 1.95 mg/pill 
 
